cats20170331

0001437749-17-009273.txt : 20170515 0001437749-17-009273.hdr.sgml : 20170515 20170515170726 ACCESSION NUMBER: 0001437749-17-009273 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 39 CONFORMED PERIOD OF REPORT: 20170331 FILED AS OF DATE: 20170515 DATE AS OF CHANGE: 20170515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CATASYS, INC. CENTRAL INDEX KEY: 0001136174 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 880464853 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-31932 FILM NUMBER: 17845609 BUSINESS ADDRESS: STREET 1: 11601 WILSHIRE BLVD. STREET 2: SUITE 1100 CITY: LOS ANGELES STATE: CA ZIP: 90025 BUSINESS PHONE: 310 444 4300 MAIL ADDRESS: STREET 1: 11601 WILSHIRE BLVD. STREET 2: SUITE 1100 CITY: LOS ANGELES STATE: CA ZIP: 90025 FORMER COMPANY: FORMER CONFORMED NAME: HYTHIAM, INC. DATE OF NAME CHANGE: 20101029 FORMER COMPANY: FORMER CONFORMED NAME: HYTHIAM INC DATE OF NAME CHANGE: 20031003 FORMER COMPANY: FORMER CONFORMED NAME: ALASKA FREIGHTWAYS INC DATE OF NAME CHANGE: 20010305 10-Q 1 cats20170331_10q.htm FORM 10-Q cats20170331_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________________

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2017

Commission File Number 001-31932

_______________________

CATASYS, INC.

(Exact name of registrant as specified in its charter)

_______________________

Delaware	88-0464853
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

11601 Wilshire Boulevard, Suite 1100, Los Angeles, California 90025

(Address of principal executive offices, including zip code)

(310) 444-4300

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☑ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☑

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

As of May 12, 2017, there were 15,874,678 shares of registrant's common stock, $0.0001 par value, outstanding.

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION			4

	ITEM 1. Financial Statements		4

		Condensed Consolidated Balance Sheets as of March 31, 2017 (unaudited) and December 31, 2016	4

		Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2017 and 2016 (unaudited)	5

		Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2017 and 2016 (unaudited)	6

		Notes to Condensed Consolidated Financial Statements	7

	ITEM 2. Management's Discussion and Analysis of FinancialCondition and Results of Operations		15

	ITEM 3. Quantitative and Qualitative Disclosures About Market Risk		22

	ITEM 4. Controls and Procedures		22

PART II – OTHER INFORMATION			24

	ITEM 1. Legal Proceedings		24

	ITEM 1A. Risk Factors		24

	ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds		27

	ITEM 3. Defaults Upon Senior Securities		27

	ITEM 4. Mine Safety Disclosures		27

	ITEM 5. Other Information		27

	ITEM 6. Exhibits		27

In this Quarterly Report on Form 10-Q, except as otherwise stated or the context otherwise requires, the terms “we,” “us” “our” or the “Company” refer to Catasys, Inc. and our wholly-owned subsidiaries. Our common stock, par value $0.0001 per share, is referred to as “common stock.”

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

CATASYS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS


	(unaudited)
(In thousands, except for number of shares)	March 31,			December 31,
	2017			2016
ASSETS
Current assets
Cash and cash equivalents	$	291		$	851
Receivables, net of allowance for doubtful accounts of $149 and $0, respectively		1,263			1,052
Prepaids and other current assets		596			420
Total current assets		2,150			2,323
Long-term assets
Property and equipment, net of accumulated depreciation of $1,660 and $1,620, respectively		419			410
Deposits and other assets		371			371
Total Assets	$	2,940		$	3,104

LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities
Accounts payable	$	1,221		$	870
Accrued compensation and benefits		2,020			2,089
Deferred revenue		1,943			1,525
Other accrued liabilities		582			575
Short term debt, related party, net of discount $0 and $216, respectively		10,046			9,796
Derivative liability		18,718			8,122
Total current liabilities		34,530			22,977
Long-term liabilities
Deferred rent and other long-term liabilities		95			117
Capital leases		22			31
Warrant liabilities		12,893			5,307
Total Liabilities		47,540			28,432

Stockholders' deficit
Preferred stock, $0.0001 par value; 50,000,000 shares authorized; no shares issued and outstanding		-			-
Common stock, $0.0001 par value; 500,000,000 shares authorized; 9,443,749 and 9,214,743 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively		6			6
Additional paid-in-capital		256,881			254,385
Accumulated deficit		(301,487	)		(279,719	)
Total Stockholders' Deficit		(44,600	)		(25,328	)
Total Liabilities and Stockholders' Deficit	$	2,940		$	3,104

*The financial statements have been retroactively restated to reflect the 6-for-1 reverse-stock split that occurred on April 25, 2017.

See accompanying notes to the condensed consolidated financial statements.

CATASYS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

	Three Months Ended
(In thousands, except per share amounts)	March 31,
	2017			2016
Revenues
Healthcare services revenues	$	1,822		$	728

Operating expenses
Cost of healthcare services		1,365			966
General and administrative		2,629			2,187
Depreciation and amortization		39			32
Total operating expenses		4,033			3,185

Loss from operations		(2,211	)		(2,457	)

Other income		14			65
Interest expense		(2,867	)		(333	)
Loss on conversion of note		(926	)		-
Change in fair value of warrant liability		(5,181	)		(228	)
Change in fair value of derivative liability		(10,596	)		(1,337	)
Loss from operations before provision for income taxes		(21,767	)		(4,290	)
Provision for income taxes		1			2
Net Loss	$	(21,768	)	$	(4,292	)

Basic and diluted net loss from operations per share:	$	(2.35	)	$	(0.47	)

Basic and diluted weighted number of shares outstanding		9,246			9,168

*The financial statements have been retroactively restated to reflect the 6-for-1 reverse-stock split that occurred on April 25, 2017.

See accompanying notes to the condensed consolidated financial statements.

CATASYS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(unaudited)

	Three Months Ended
(In thousands)	March 31,
	2017			2016
Operating activities:
Net loss	$	(21,768	)	$	(4,292	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		39			32
Issuance costs included in interest expense		2,622			216
Provision for doubtful accounts		149			7
Deferred rent		(20	)		(23	)
Share-based compensation expense		127			174
Fair value adjustment on derivative liability		10,596			1,337
Fair value adjustment on warrant liability		5,181			228
Shares issued for services		117			-
Loss on conversion of note		926			-
Changes in current assets and liabilities:
Receivables		(360	)		(27	)
Prepaids and other current assets		(176	)		141
Deferred revenue		418			593
Accounts payable and other accrued liabilities		534			96
Net cash used in operating activities	$	(1,615	)	$	(1,518	)

Investing activities:
Purchases of property and equipment	$	(49	)	$	(10	)
Deposits and other assets		-			16
Net cash provided by/(used in) investing activities	$	(49	)	$	6

Financing activities:
Proceeds from bridge loan	$	1,115		$	900
Capital lease obligations		(11	)		(42	)
Net cash provided by financing activities	$	1,104		$	858

Net decrease in cash and cash equivalents	$	(560	)	$	(654	)
Cash and cash equivalents at beginning of period		851			916
Cash and cash equivalents at end of period	$	291		$	262

Supplemental disclosure of cash paid
Income taxes	$	39		$	26
Supplemental disclosure of non-cash activity
Common stock issued for investor relations services	$	117		$	-

See accompanying notes to the condensed consolidated financial statements.

Catasys, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 1. Basis of Consolidation, Presentation and Going Concern

The accompanying unaudited condensed consolidated financial statements for Catasys, Inc. and its subsidiaries have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and instructions to Form 10-Q and, therefore, do not include all disclosures necessary for a complete presentation of financial position, results of operations, and cash flows in conformity with U.S. GAAP. In our opinion, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of the results that may be expected for the entire fiscal year. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto included in our most recent Annual Report on Form 10-K for the year-ended December 31, 2016, from which the balance sheets, as of December 31, 2016, have been derived.

Our financial statements have been prepared on the basis that we will continue as a going concern. At March 31, 2017, cash and cash equivalents was $291,000 and we had a working capital deficit of approximately $32.4 million. We have incurred significant operating losses and negative cash flows from operations since our inception. During the three months ended March 31, 2017, our cash used in operating activities was $1.6 million. We anticipate that we could continue to incur negative cash flows and net losses for the next twelve months. The financial statements do not include any adjustments relating to the recoverability of the carrying amount of the recorded assets or the amount of liabilities that might result from the outcome of this uncertainty. As of March 31, 2017, these conditions raised substantial doubt as to our ability to continue as a going concern. In April 2017, we closed on a public offering for aggregate gross proceeds of $16.5 million prior to deducting underwriter discounts, commission and other estimated offering expenses. We expect our current cash resources to cover expenses through at least the next twelve month.

Note 2. Summary of Significant Accounting Policies

Revenue Recognition

Our Catasys contracts are generally designed to provide cash fees to us on a monthly basis or an upfront case rate based on enrolled members. To the extent our contracts may include a minimum performance guarantee; we reserve a portion of the fees that may be at risk until the performance measurement period is completed. To the extent we receive case rates or other fees in advance that are not subject to the performance guarantees, we recognize the case rate ratably over the twelve months of our program. We recognize any fees from sharing in the savings generated from enrolled members when we receive payment.

Cost of Services

Cost of healthcare services consists primarily of salaries related to our care coaches, outreach specialists and other staff directly involved in member care, healthcare provider claims payments, and fees charged by our third party administrators for processing these claims. Salaries and fees charged by our third party administrators for processing claims are expensed when incurred and healthcare provider claims payments are recognized in the period in which an eligible member receives services. We contract with doctors and licensed behavioral healthcare professionals, on a fee-for-service basis. We determine that a member has received services when we receive a claim or in the absence of a claim, by utilizing member data recorded in the eOnTrak^TMdatabase within the contracted timeframe, with all required billing elements correctly completed by the service provider.

Cash Equivalents and Concentration of Credit Risk

We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Cash is deposited with what we believe are highly credited, quality financial institutions. The deposited cash may exceed Federal Deposit Insurance Corporation (“FDIC”) insured limits. As of March 31, 2017, cash and cash equivalents exceeding federally insured limits totaled $115,038.

For the three months ended March 31, 2017, three customers accounted for approximately 94% of revenues and two customers accounted for approximately 79% of accounts receivable.

Basic and Diluted Income (Loss) per Share

Basic income (loss) per share is computed by dividing the net income (loss) to common stockholders for the period by the weighted average number of common stock outstanding during the period. Diluted income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of common stock and dilutive common equivalent shares outstanding during the period.

Common equivalent shares, consisting of 1,928,431 and 620,119 common shares for the three months ended March 31, 2017 and 2016, respectively, issuable upon the exercise of stock options and warrants have been excluded from the diluted earnings per share calculation as their effect is anti-dilutive.

Share-Based Compensation

Our 2017 Stock Incentive Plan (the “2017 Plan”), provides for the issuance of up to 2,333,334 shares of our common stock. Incentive stock options (ISOs) under Section 422A of the Internal Revenue Code and non-qualified options (NSOs) are authorized under the Plan. We have granted stock options to executive officers, employees, members of our board of directors, and certain outside consultants. The terms and conditions upon which options become exercisable vary among grants, but option rights expire no later than ten years from the date of grant and employee and board of director awards generally vest over three to five years. As of March 31, 2017, we had 243,853 vested and unvested shares outstanding and 50,774 shares available for future awards under the Plan.

Total share-based compensation expense on a consolidated basis was $127,000 and $174,000 for the three months ended March 31, 2017 and 2016, respectively.

Stock Options – Employees and Directors

We measure and recognize compensation expense for all share-based payment awards made to employees and directors based on estimated fair values on the date of grant. We estimate the fair value of share-based payment awards using the Black-Scholes option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the consolidated statements of operations.

Share-based compensation expense recognized for employees and directors for the three months ended March 31, 2017 and 2016 was $127,000 and $174,000, respectively.

For share-based awards issued to employees and directors, share-based compensation is attributed to expense using the straight-line single option method. Share-based compensation expense recognized in our consolidated statements of operations for the three months ended March 31, 2017 and 2016, is based on awards ultimately expected to vest, reduced for estimated forfeitures. Accounting rules for stock options require forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

There were no options granted to employees and directors during the three months ended March 31, 2017 and 2016, respectively, under the 2017 Plan. Employee and director stock option activity for the three months ended March 31, 2017 are as follows:

			Weighted Avg.
	Shares		Exercise Price
Balance December 31, 2016		244,000	$	39.06

Granted		-	$	-
Cancelled		-	$	-

Balance March 31, 2017		244,000	$	38.90

The expected volatility assumptions have been based on the historical and expected volatility of our stock, measured over a period generally commensurate with the expected term. The weighted average expected option term for the three months ended March 31, 2017 and 2016, reflects the application of the simplified method prescribed in SEC Staff Accounting Bulletin (“SAB”) No. 107 (as amended by SAB 110), which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches.

As of March 31, 2017, there was $191,000 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plan. That cost is expected to be recognized over a weighted-average period of approximately 1.52 years.

Stock Options and Warrants – Non-employees

We account for the issuance of options and warrants for services from non-employees by estimating the fair value of warrants issued using the Black-Scholes pricing model. This model’s calculations include the option or warrant exercise price, the market price of shares on grant date, the weighted average risk-free interest rate, the expected life of the option or warrant, and the expected volatility of our stock and the expected dividends.

For options and warrants issued as compensation to non-employees for services that are fully vested and non-forfeitable at the time of issuance, the estimated value is recorded in equity and expensed when the services are performed and benefit is received. For unvested shares, the change in fair value during the period is recognized in expense using the graded vesting method.

There were no options issued to non-employees for the three months ended March 31, 2017 and 2016, respectively. There was no share-based compensation expense relating to stock options and warrants recognized for the non-employees for the three months ended March 31, 2017 and 2016, respectively.

Common Stock

There were 14,492 and 0 shares of common stock issued in exchange for investor relations services during the three months ended March 31, 2017 and 2016, respectively. Generally, the costs associated with shares issued for services are amortized to the related expense on a straight-line basis over the related service periods.

There were 214,514 shares of common stock issued to Shamus, LLC (“Shamus”), a Company owned by David E. Smith, a member of our board of directors for the conversion of their December 2016 Convertible Debentures.

Income Taxes

We have recorded a full valuation allowance against our otherwise recognizable deferred tax assets as of March 31, 2017. As such, we have not recorded a provision for income tax for the period ended March 31, 2017. We utilize the liability method of accounting for income taxes as set forth in ASC 740, Income Taxes. Under the liability method, deferred taxes are determined based on the temporary differences between the financial statement and tax basis of assets and liabilities using tax rates expected to be in effect during the years in which the basis differences reverse. A valuation allowance is recorded when it is more likely than not that some of the deferred tax assets will not be realized.

We assess our income tax positions and record tax benefits for all years subject to examination based upon our evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where there is greater than 50% likelihood that a tax benefit will be sustained, we have recorded the largest amount of tax benefit that may potentially be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is less than 50% likelihood that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements. Based on management's assessment of the facts, circumstances and information available, management has determined that all of the tax benefits for the period ended March 31, 2017 should be realized.

Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure fair value. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level I) and the lowest priority to unobservable inputs (Level III). The three levels of the fair value hierarchy are described below:

Level Input:		Input Definition:
Level I		Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
Level II		Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.
Level III		Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.

The following table summarizes fair value measurements by level at March 31, 2017 for assets and liabilities measured at fair value:

	Balance at March 31, 2017


*(Amounts in thousands)*	Level I		Level II		Level III		Total
Certificates of deposit		106		-		-		106
Total assets		106		-		-		106

Warrant liabilities		-		-		12,893		12,893
Derivative Liability						18,718		18,718
Total liabilities		-		-		31,611		31,611

Carrying amounts reported in the condensed consolidated balance sheets of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate fair value due to their relatively short maturity. The fair value of borrowings is not considered to be significantly different from its carrying amount because stated rates for such debt reflect current market rates and conditions.

Financial instruments classified as Level III in the fair value hierarchy as of March 31, 2017, represent our liabilities measured at market value on a recurring basis which include warrant liabilities and derivative liabilities resulting from recent debt and equity financings. In accordance with current accounting rules, the warrant liabilities and derivative liabilities are being marked-to-market each quarter-end until they are completely settled or expire. The warrants and derivative liabilities are valued using the Black-Scholes option-pricing model, using both observable and unobservable inputs and assumptions consistent with those used in our estimate of fair value of employee stock options. See Warrant Liabilities below.

The following table summarizes our fair value measurements using significant Level III inputs, and changes therein, for the three months ended March 31, 2017:

	Level III			Level III
	Warrant			Derivative
*(Dollars in thousands)*	Liabilities		*(Dollars in thousands)*	Liabilities
Balance as of December 31, 2016	$	5,307	Balance as of December 31, 2016	$	8,122
Issuance of warrants		2,405	Issuance of warrants		-
Change in fair value		5,181	Change in fair value		10,596
Balance as of March 31, 2017	$	12,893	Balance as of March 31, 2017	$	18,718

Issuance (exercise) of warrants, net		-	Issuance (exercise) of warrants, net		-
Change in fair value		-	Change in fair value		-
Balance as of June 30, 2016	$	12,893	Balance as of June 30, 2016	$	18,718

Issuance (exercise) of warrants, net		-	Issuance (exercise) of warrants, net		-
Expiration of warrants		-	Expiration of warrants		-
Change in fair value		-	Change in fair value		-
Balance as of September 30, 2016	$	12,893	Balance as of September 30, 2016	$	18,718

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation. Additions and improvements to property and equipment are capitalized at cost. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, which range from two to seven years for furniture and equipment. Leasehold improvements are amortized over the lesser of the estimated useful lives of the assets or the related lease term, which is typically five to seven years.

Warrant Liabilities

In January 2017, we entered into a Subscription Agreement (the “Subscription Agreement”) with Acuitas Group Holdings, LLC (“Acuitas”), one hundred percent (100%) of which is owned by Terren S. Peizer, Chairman and Chief Executive Officer of the Company, pursuant to which we will receive aggregate gross proceeds of $1,300,000 (the “Loan Amount”) in consideration of the issuance of (i) an 8% Series B Convertible Debenture due March 31, 2017 (the “January 2017 Convertible Debenture”) and (ii) five-year warrants to purchase shares of the Company’s common stock in an amount equal to one hundred percent (100%) of the initial number of shares of common stock issuable upon the conversion of the January 2017 Convertible Debenture, at an exercise price of $5.10 per share (the “January 2017 Warrants”). The Loan Amount is payable in tranches through March 31, 2017, and as of March 31, 2017 we have received $1,115,000. In addition, any warrants issued in conjunction with the December 2016 Convertible Debenture currently outstanding with Acuitas have been increased by an additional 25% warrant coverage, exercisable for an aggregate of 137,883 shares of the Company’s common stock. Acuitas agreed to extend the maturity date of the January 2017 Convertible Debenture to April 30, 2017 or until we complete a public offering, whichever comes first.

The January 2017 Warrants include, among other things, price protection provisions pursuant to which, subject to certain exempt issuances, the then exercise price of the January 2017 Warrants will be adjusted if the Company issues shares of common stock at a price that is less than the then exercise price of the January 2017 Warrants. Such price protection provisions will remain in effect until the earliest of (i) the termination date of the January 2017 Warrants, (ii) such time as the January 2017 Warrants are exercised or (iii) contemporaneously with the listing of the Company’s shares of common stock on a registered national securities exchange.

In connection with the Subscription Agreement described above, the number of Shamus warrants issued as part of the December 2016 Convertible Debenture were increased from 75% to 100% warrant coverage, exercisable for an aggregate of 58,824 shares of the Company’s common stock.

The warrant liabilities were calculated using the Black-Scholes model based upon the following assumptions:

	March 31, 2017
Expected volatility		93.56%
Risk-free interest rate	1.27	-	1.93%
Weighted average expected lives in years	2	-	5
Expected dividend		0%

We have issued warrants to purchase common stock in February 2012, April 2015, July 2015, August 2016, December 2016, January 2017, February 2017 and March 2017. The warrants are being accounted for as liabilities in accordance with FASB accounting rules, due to anti-dilution provisions in some warrants that protect the holders from declines in our stock price, which is considered outside our control. The warrants are marked-to-market each reporting period, using the Black-Scholes pricing model, until they are completely settled or expire.

For the three months ended March 31, 2017 and 2016, we recognized a loss of $5.2 million and $228,000, respectively, related to the revaluation of our warrant liabilities.

Derivative Liability

In July 2015, we entered into a $3.55 million 12% Original Issue Discount Convertible Debenture due January 18, 2016 with Acuitas (the “July 2015 Convertible Debenture”). The conversion price of the July 2015 Convertible Debenture is $11.40 per share, subject to adjustments, including for issuances of common stock and common stock equivalents below the then current conversion or exercise price, as the case may be. In October 2015, we entered into an amendment of the July 2015 Convertible Debenture which extended the maturity date of the July 2015 Convertible Debenture from January 18, 2016 to January 18, 2017. In addition, the conversion price of the July 2015 Convertible Debenture was subsequently adjusted to $1.80 per share. The July 2015 Convertible Debenture is unsecured, bears interest at a rate of 12% per annum payable in cash or shares of common stock, subject to certain conditions, at our option, and is subject to mandatory prepayment upon the consummation of certain future financings. Acuitas agreed to extend the maturity date of the July 2015 Convertible Debenture to April 30, 2017 or until we complete a public offering, whichever comes first. The derivative liability associated with the July 2015 Convertible Debenture was calculated using the Black-Scholes model based upon the following assumptions:

	March 31, 2017
Expected volatility		93.56	%
Risk-free interest rate		0.74	%
Weighted average expected lives in years		0.08
Expected dividend		0	%

For the three months ended March 31, 2017 and 2016, we recognized a loss of $10.6 million and $1.3 million related to the revaluation of our derivative liability, respectively.

Recently Issued or Newly Adopted Accounting Standards

In April 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-10, Revenue from Contracts with Customers (Topic 606), which amends certain aspects of the Board’s new revenue standard, ASU 2014-09, Revenue from Contracts with Customers. The standard should be adopted concurrently with adoption of ASU 2014-09, which is effective for annual and interim periods beginning after December 15, 2017. Early adoption is permitted. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

In March 2016, the FASB issued ASU 2016-09, Compensation — Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”), which outlines new provisions intended to simplify various aspects related to accounting for share-based payments and their presentation in the financial statements. The standard is effective for the Company for fiscal years beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted. The adoption of ASU 2016-09 did not have a material effect on our consolidated financial positon or results of operations.

In February 2015, the FASB issued ASU, Consolidation (Topic 810): Amendments to the Consolidation Analysis (“ASU 2015-02”). ASU 2015-02 modifies existing consolidation guidance for reporting organizations that are required to evaluate whether they should consolidate certain legal entities. ASU 2015-02 is effective for fiscal years and interim periods within those years beginning after December 15, 2015, and requires either a retrospective or a modified retrospective approach to adoptions. The adoption of ASU 2015-02 did not have a material effect on our consolidated financial position or results of operations.

In August 2014, the FASB issued FASB ASU 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 changes the disclosure of uncertainties about an entity’s ability to continue as a going concern. Under U.S. GAAP, continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Even if an entity’s liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. Because there is no guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related note disclosures, there is diversity in practice whether, when, and how an entity discloses the relevant conditions and events in its financial statements. As a result, these changes require an entity’s management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that financial statements are issued. Substantial doubt is defined as an indication that it is probable that an entity will be unable to meet its obligations as they become due within one year after the date that financial statements are issued. If management has concluded that substantial doubt exists, then the following disclosures should be made in the financial statements: (i) principal conditions or events that raised the substantial doubt, (ii) management’s evaluation of the significance of those conditions or events in relation to the entity’s ability to meet its obligations, (iii) management’s plans that alleviated the initial substantial doubt or, if substantial doubt was not alleviated, management’s plans that are intended to at least mitigate the conditions or events that raise substantial doubt, and (iv) if the latter in (iii) is disclosed, an explicit statement that there is substantial doubt about the entity’s ability to continue as a going concern. ASU 2014-15 is effective for periods beginning after December 15, 2016. The adoption of ASU 2014-15 did not have a material effect on our consolidated position or results of operations.

Note 3. Related Party Disclosure

In January 2017, we entered into the Subscription Agreement with Acuitas pursuant to which we will receive aggregate gross proceeds of $1,300,000 (the “Loan Amount”) in consideration of the issuance of the January 2017 Convertible Debenture and the January 2017 Warrants The Loan Amount is payable in tranches through March 31, 2017, and as of March 31, 2017 we have received $1,115,000. In addition, any warrants issued in conjunction with the December 2016 Convertible Debenture currently outstanding with Acuitas have been increased by an additional 25% warrant coverage, exercisable for an aggregate of 137,883 shares of the Company’s common stock.

In addition, we have accounts payable outstanding with Mr. Peizer for travel and expenses of $204,000 as of March 31, 2017 and deferred salary of $1.1 million as of March 31, 2017.

In January 2017, in connection with the Subscription Agreement described above, the number of Shamus warrants issued as part of the December 2016 Convertible Debenture were increased from 75% to 100% warrant coverage, exercisable for an aggregate of 14,706 shares of the Company’s common stock.

In March 2017, Shamus converted $1.3 million of their December 2016 Convertible Debentures and accrued interest for 214,514 shares of our common stock.

Note 4. Short-term Debt

In January 2017, we entered into a Subscription Agreement (the “Subscription Agreement”) with Acuitas,, pursuant to which we will receive aggregate gross proceeds of $1,300,000 (the “Loan Amount”) in consideration of the issuance of (i) an 8% Series B Convertible Debenture due March 31, 2017 (the “January 2017 Convertible Debenture”) and (ii) five-year warrants to purchase shares of the Company’s common stock in an amount equal to one hundred percent (100%) of the initial number of shares of common stock issuable upon the conversion of the January 2017 Convertible Debenture, at an exercise price of $5.10 per share (the “January 2017 Warrants”). The Loan Amount is payable in tranches through March 31, 2017, and as of March 31, 2017 we have received $1,115,000. In addition, any warrants issued in conjunction with the December 2016 Convertible Debenture currently outstanding with Acuitas have been increased by an additional 25% warrant coverage, exercisable for an aggregate of 137,883 shares of the Company’s common stock. Acuitas agreed to extend the maturity date of the January 2017 Convertible Debenture to April 30, 2017 or until we complete a public offering, whichever comes first.

Note 5. Restatement of Financial Statements

The financial statements have been retroactively restated to reflect the 1-for-6 reverse-stock split that occurred on April 25, 2017.

Note 6. Subsequent Event

Amendments to Outstanding Warrants and Extension of Existing Debentures

In March 2017, we entered into amendments with the holders of certain outstanding warrants issued on April 17, 2015 and July 30, 2015 to eliminate certain anti-dilution provisions in such warrants, which caused us to reflect an associated liability of $12.8 million on our balance sheet as of March 31, 2017. Such amendments did not take effect until April 28, 2017. For each warrant share underlying the warrants so amended, the holder received the right to purchase an additional .2 shares of common stock. Two of the holders of such warrants, which owners hold warrants to purchase an aggregate of 11,049 shares of common stock, did not agree to the amendment. The warrant holders agreeing to the amendment include Acuitas and another accredited investor.

Additionally, in March 2017, we and the holders of an aggregate of approximately $10 million of our existing convertible debentures agreed to extend the maturity dates of such debentures until April 28, 2017.

Reverse Stock Split

On April 21, 2017, we filed a certificate of amendment to our Certificate of Incorporation, as amended and in effect, with the Secretary of State of the State of Delaware, implementing a 1-for-6 reverse stock split of the Company's common stock, pursuant to which each six shares of issued and outstanding common stock converted into one share of common stock. Proportionate voting rights and other rights of common stock holders will not be affected by the reverse stock split. No fractional shares of common stock were issued as a result of the reverse stock split; stockholders were paid cash in lieu of any such fractional shares. The 1-for-6 reverse stock split became effective at 5:00 p.m., Eastern Time, on April 24, 2017, and our common stock began trading on the OTCQB Marketplace on a post-split basis at the open of trading on April 25, 2017. Our post-reverse split common stock has a new CUSIP number: 149049 504. Other terms of the common stock are not affected by the reverse stock split. The common stock will continue to trade under the symbol "CATS."

All stock options and warrants to purchase common stock outstanding and our Common Stock reserved for issuance under the Company's equity incentive plans immediately prior to the reverse stock split were appropriately adjusted by dividing the number of affected shares of common stock by six and, as applicable, multiplying the exercise price by six as a result of the reverse stock split.

Public Offering

On April 25, 2017, we entered into an underwriting agreement with Joseph Gunnar & Co., LLC, as underwriter in connection with a public offering of the Company’s securities. Pursuant to the underwriting agreement, we agreed to issue and sell an aggregate of 3,125,000 shares of Common Stock at a public offering price of $4.80 per share, and the purchase price to the underwriter after discounts and commissions was $4.464 per share. The closing of the offering occurred on April 28, 2017. The Company received $14.8 million in net proceeds in connection with this offering.

Pursuant to the underwriting agreement, we issued to the underwriter a warrant for the purchase of an aggregate of 156,250 shares of Common Stock for an aggregate purchase price of $100. The exercise price of the warrant is equal to 125% of the public offering price in the offering, or $6.00 per share of Common Stock.

NASDAQ Uplisting

In connection with the public offering, our Common Stock began trading on the NASDAQ Capital Market under the symbol “CATS” beginning on April 26, 2017.

Exercise of Over-Allotment Option

Pursuant to the underwriting with Joseph Gunnar & Co., LLC dated April 25, 2017, we agreed to issue to the underwriters a 45-day over-allotment option to purchase up to 468,750 additional shares of Common Stock at the public offering price less the applicable underwriter discount. On May 2, 2017, the underwriter acquired an additional 303,750 shares pursuant to such over-allotment option.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements, including the related notes, and the other financial information included elsewhere in this report. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” included elsewhere in this report and our annual report filed on Form 10-K for the year ended December 31, 2016.

CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING INFORMATION

This report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to the financial condition, results of operations, business strategies, operating efficiencies or synergies, competitive positions, growth opportunities for existing products, plans and objectives of management, markets for our stock and other matters. Statements in this report that are not historical facts are hereby identified as “forward-looking statements” for the purpose of the safe harbor provided by Section 21E of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”) and Section 27A of the Securities Act of 1933, as amended. Such forward-looking statements, including, without limitation, those relating to future business prospects, our revenue and income, wherever they occur, are necessarily estimates reflecting the best judgment of our senior management as of the date on which they were made, or if no date is stated, as of the date of this report. These forward-looking statements are subject to risks, uncertainties and assumptions, including those described in the “Risk Factors” in Item 1A of Part I of our most recent Annual Report on Form 10-K (“Form 10-K”) for the fiscal year ended December 31, 2016 and other reports we filed with the Securities and Exchange Commission (“SEC”), that may affect the operations, performance, development and results of our business. Because the factors discussed in this report could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any such forward-looking statements. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We assume no obligation and do not intend to update these forward looking statements, except as required by law.

OVERVIEW

General

We provide data analytics based specialized behavioral health management and integrated treatment services to health plans through our OnTrak solution. Our OnTrak solution is designed to improve member health and at the same time lower costs to the insurer for underserved populations where behavioral health conditions are causing or exacerbating co-existing medical conditions. The program utilizes proprietary analytics, member engagement and patient centric treatment that integrates evidence-based medical and psychosocial interventions along with care coaching in a 52-week outpatient program. Our initial focus was members with substance use disorders, but we have expanded our solution to assist members with anxiety and depression. We currently operate our OnTrak solutions in Florida, Georgia, Illinois, Kansas, Kentucky, Louisiana, Massachusetts, Missouri, New Jersey, North Carolina, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Virginia, West Virginia and Wisconsin. We provide services to commercial (employer funded), managed Medicare Advantage, and managed Medicaid and duel eligible (Medicare and Medicaid) populations.

Recent Developments

New Directors

On March 11, 2017, our Board of Directors appointed Marc Cummins and Richard J. Berman to serve on our Board of Directors and our Audit Committee, effective immediately. There are no arrangements or understandings between Messrs. Cummins or Berman and any other person pursuant to which they were appointed as our directors. There are no transactions to which we are a party and in which Messrs. Cummins or Berman have a material interest that are required to be disclosed under Item 404(a) of Regulation S-K. Mr. Cummins previously served on our Board of Directors until his resignation on December 15, 2010, and Mr. Berman has not previously held any position at the Company. Neither individual has family relations with any of our directors or executive officers.

Amendments to Outstanding Warrants and Extension of Existing Debentures

Reverse Stock Split

Public Offering

NASDAQ Uplisting

In connection with the public offering, our Common Stock began trading on the NASDAQ Capital Market under the symbol “CATS” beginning on April 26, 2017.

Exercise of Over-Allotment Option

Operations

We currently operate our OnTrak solutions in Florida, Georgia, Illinois, Kansas, Kentucky, Louisiana, Massachusetts, Missouri, New Jersey, North Carolina, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Virginia, West Virginia and Wisconsin. We provide services to commercial (employer funded), managed Medicare Advantage, and managed Medicaid and duel eligible (Medicare and Medicaid) populations. We have generated fees from our launched programs and expect to launch additional customers and increase enrollment and fees throughout 2017. However, there can be no assurance that we will generate such fees or that new programs will launch as we expect.

RESULTS OF OPERATIONS

Table of Summary Consolidated Financial Information

The table below and the discussion that follows summarize our results of consolidated operations for the three months ended March 31, 2017 compared to the three months ended March 31, 2016:

	Three Months Ended
(In thousands, except per share amounts)	March 31,
	2017			2016
Revenues
Healthcare services revenues	$	1,822		$	728

Operating expenses
Cost of healthcare services		1,365			966
General and administrative		2,629			2,187
Depreciation and amortization		39			32
Total operating expenses		4,033			3,185

Loss from operations		(2,211	)		(2,457	)

Other income		14			65
Interest expense		(2,867	)		(333	)
Loss on conversion of note		(926	)		-
Change in fair value of warrant liability		(5,181	)		(228	)
Change in fair value of derivative liability		(10,596	)		(1,337	)
Loss from operations before provision for income taxes		(21,767	)		(4,290	)
Provision for income taxes		1			2
Net Loss	$	(21,768	)	$	(4,292	)

Basic and diluted net loss from operations per share:	$	(2.35	)	$	(0.47	)

Basic and diluted weighted number of shares outstanding		9,246			9,168

Summary of Consolidated Operating Results

Loss from operations before provision for income taxes for the three months ended March 31, 2017 was $21.8 million, compared with a net loss of $4.3 million for the same period in 2016. The difference primarily relates to the increase in the loss from change in fair value of warrant liability, the increase in the loss from change in fair value of the derivative liability, and the increase in interest expense for the three months ended March 31, 2017, compared to the same period in 2016.

Revenues

During the three months ended March 31, 2017, we have expanded OnTrak for one customer into two new lines of business and have continued to increase enrollment, which was offset to some extent by two customers exiting certain health exchange and Medicaid markets, which has resulted in a net increase in the number of patients enrolled in our solutions compared with the same period in 2016. For the three months ended March 31, 2017, enrollment increased by more than 13% over the same period in 2016. Recognized revenue increased by $1.1 million, or 150%, for the three months ended March 31, 2017, compared with the same period in 2016. We reserve a portion, and in some cases all, of the fees we receive related to enrolled members, as the fees are subject to performance guarantees or are received as case rates in advance at the time of enrollment. Fees deferred for performance guarantees are recognized when those guarantees are satisfied and fees received in advance are recognized ratably over the period of enrollment. Deferred revenue increased by $418,000 since December 31, 2016.

Cost of Healthcare Services

Cost of healthcare services consists primarily of salaries related to our care coaches, healthcare provider claims payments to our network of physicians and psychologists, and fees charged by our third party administrators for processing these claims. The increase of $399,000 for the three months ended March 31, 2017, compared with the same period in 2016, relates primarily to the increase in members being treated, the addition of care coaches, outreach staff, community care coordinators and other staff to manage the increasing number of enrolled members. In addition, we hire staff in preparation for anticipated future customer contracts and corresponding increases in members eligible for OnTrak. The costs for such staff are included in Cost of Healthcare Services during training and ramp-up periods.

General and Administrative Expenses

Total general and administrative expense increased by $443,000 for the three months ended March 31, 2017, compared with the same period in 2016. The increase was due primarily to an increase in legal and investor relations services during the first quarter of 2017.

Depreciation and Amortization

Depreciation and amortization was immaterial for the three months ended March 31, 2017 and 2016, respectively.

Interest Expense

Interest expense increased by $2.5 million for the three months ended March 31, 2017, compared with the same period in 2016. The increase related to the issuance of warrants as part of our January 2017 financings as well as interest related to the December 2016 and January 2017 Convertible Debentures.

Loss of conversion of note

Loss on conversion of note relates to the conversion of a portion of the December 2016 Convertible Debentures. No such conversion occurred during 2016.

Change in fair value of warrant liability

We have issued warrants to purchase common stock in February 2012, April 2015, July 2015, August 2016, December 2016, January 2017, February 2017, and March 2017. The warrants are being accounted for as liabilities in accordance with FASB accounting rules, due to anti-dilution provisions in the warrants that protect the holders from declines in our stock price and a requirement to deliver registered shares upon exercise of the warrants, which is considered outside our control. The warrants are marked-to-market each reporting period, using the Black-Scholes pricing model, until they are completely settled or expire.

The increase in the loss from change in fair value for the warrants was $5.0 million for the three months ended March 31, 2017 compared with the same period in 2016.

We will continue to mark-to-market the warrants to market value each quarter until they are completely settled or expire.

Change in fair value of derivative liability

The increase in the loss from change in fair value of derivative liabilities was $9.3 million for the three months ended March 31, 2017 compared with the same period in 2016. The derivative liability was the result of the issuance of the July 2015 Convertible Debenture.

We will continue to mark-to-market the derivative liability each quarter until they are completely settled.

LIQUIDITY AND CAPITAL RESOURCES

Liquidity

As of May 12, 2017, we had a balance of approximately $10.1 million cash on hand. We had a working capital deficit of approximately $32.4 million at March 31, 2017. We have incurred significant operating losses and negative operating cash flows since our inception. We could continue to incur negative cash flows and operating losses for the next twelve months. Our current cash burn rate is approximately $488,000 per month, excluding non-current accrued liability payments. In April 2017, we closed on a public offering for aggregate gross proceeds of $16.5 million prior to deducting underwriter discounts, commission and other estimated offering expenses. We expect our current cash resources to cover expenses through at least the next twelve months.

Cash Flows

We used $1.6 million of cash from operating activities during the three months ended March 31, 2017 compared with $1.5 million in the same period in 2016. The increase in cash used in operating activities reflects the increase in the number of members being treated, the addition of care coaches and clinical care coordinators to our staff to manage the increasing number of enrolled members, and the expansion of our program in Kansas to cover high cost members with anxiety disorders. Significant non-cash adjustments to operating activities for the three months ended March 31, 2017 included a fair value adjustment on derivative liability of $10.6 million, a fair value adjustment on warrant liability of $5.2 million, a loss on conversion of note of $926,000, and issuance costs of $2.6 million related to the January 2017 Convertible Debenture.

Capital expenditures for the three months ended March 31, 2017 were not material. We anticipate that capital expenditures will increase in the future as we replace our computer systems that are reaching their useful lives, upgrade equipment to support our increased number of enrolled members, and enhance the reliability and security of our systems. These future capital expenditure requirements will depend upon many factors, including obsolescence or failure of our systems, progress with expanding the adoption of our solutions, our marketing efforts, the necessity of, and time and costs involved in obtaining, regulatory approvals, competing technological and market developments, and our ability to establish collaborative arrangements, effective commercialization, marketing activities and other arrangements.

Our net cash provided by financing activities was $1.1 million for the three months ended March 31, 2017, compared with net cash provided by financing activities of $858,000 for the three months ended March 31, 2016. Cash provided by financing activities for the three months ended March 31, 2017 consisted of the net proceeds from the convertible debenture provided by Acuitas Group Holdings, LLC (“Acuitas”), one hundred percent (100%) of which is owned by Terren S. Peizer, Chairman and Chief Executive Officer of the Company, in January 2017, leaving a balance of $291,000 in cash and cash equivalents as of March 31, 2017.

As discussed above, we currently expend cash at a rate of approximately $488,000 per month. We also anticipate cash inflow to increase during 2017 as we continue to service our executed contracts and sign new contracts. We expect our current cash resources to cover our operations through at least the next twelve months; however, delays in cash collections, revenue, or unforeseen expenditures could impact this estimate.

OFF BALANCE SHEET ARRANGEMENTS

As of March 31, 2017, we had no off-balance sheet arrangements.

CRITICAL ACCOUNTING ESTIMATES

The discussion and analysis of our financial condition and results of operations is based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities. We base our estimates on experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that may not be readily apparent from other sources. On an on-going basis, we evaluate the appropriateness of our estimates and we maintain a thorough process to review the application of our accounting policies. Our actual results may differ from these estimates.

We consider our critical accounting estimates to be those that (1) involve significant judgments and uncertainties, (2) require estimates that are more difficult for management to determine, and (3) may produce materially different results when using different assumptions. We have discussed these critical accounting estimates, the basis for their underlying assumptions and estimates and the nature of our related disclosures herein, with the audit committee of our Board of Directors. We believe our accounting policies related to the fair value of warrants, the estimation of the fair value of our derivative liability, and share-based compensation expense, involve our most significant judgments and estimates that are material to our consolidated financial statements. They are discussed further below.

Warrant Liabilities

We have issued warrants to purchase common stock in February 2012, April 2015, July 2015, August 2016, September 2016, January 2017, February 2017 and March 2017. The warrants are being accounted for as liabilities in accordance with FASB accounting rules, due to anti-dilution provisions in some warrants that protect the holders from declines in our stock price and a requirement to deliver registered shares upon exercise of the warrants, which is considered outside our control. The warrants are marked-to-market each reporting period, using the Black-Scholes pricing model, until they are completely settled or expire.

The warrant liabilities were calculated using the Black-Scholes model based upon the following assumptions:

	March 31, 2017
Expected volatility		93.56%
Risk-free interest rate	1.27	-	1.93%
Weighted average expected lives in years	2	-	5
Expected dividend		0%

For the three months ended March 31, 2017 and 2016, we recognized a loss of $5.2 million and $228,000, respectively, related to the revaluation of our warrant liabilities.

We will continue to mark the warrants to market value each reporting period, using the Black-Scholes pricing model until they are completely settled or expire.

Derivative Liabilities

In July 2015, we entered into a $3.55 million 12% Original Issue Discount Convertible Debenture due January 18, 2016 with Acuitas (the “July 2015 Convertible Debenture”). The conversion price of the July 2015 Convertible Debenture was $11.40 per share, subject to adjustments, including for issuances of common stock and common stock equivalents below the then current conversion price. In October 2015, we entered into an amendment of the July 2015 Convertible Debenture which extended the maturity date of the July 2015 Convertible Debenture from January 18, 2016 to January 18, 2017. In addition, the conversion price of the July 2015 Convertible Debenture was subsequently adjusted to $1.80 per share. The July 2015 Convertible Debenture is unsecured, bears interest at a rate of 12% per annum payable in cash or shares of common stock, subject to certain conditions, at our option, and is subject to mandatory prepayment upon the consummation of certain future financings. The derivative liability associated with the July 2015 Convertible Debenture was calculated using the Black-Scholes model based upon the following assumptions:

	March 31, 2017
Expected volatility		93.56	%
Risk-free interest rate		0.74	%
Weighted average expected lives in years		0.08
Expected dividend		0	%

For the three months ended March 31, 2017 and 2016, we recognized a loss of $10.6 million and $1.3 million related to the revaluation of our derivative liability, respectively.

Share-based compensation expense

We account for the issuance of stock, stock options, and warrants for services from non-employees based on an estimate of the fair value of options and warrants issued using the Black-Scholes pricing model. This model’s calculations include the exercise price, the market price of shares on grant date, weighted average assumptions for risk-free interest rates, expected life of the option or warrant, expected volatility of our stock and expected dividend yield.

The amounts recorded in the financial statements for share-based compensation expense could vary significantly if we were to use different assumptions. For example, the assumptions we have made for the expected volatility of our stock price have been based on the historical volatility of our stock, measured over a period generally commensurate with the expected term. If we were to use a different volatility than the actual volatility of our stock price, there may be a significant variance in the amounts of share-based compensation expense from the amounts reported. The weighted average expected option term for the three months ended March 31, 2017 and 2016, respectively, reflects the application of the simplified method set out in SEC Staff Accounting Bulletin No. 107, which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches.

From time to time, we retain terminated employees as part-time consultants upon their resignation from the Company. Because the employees continue to provide services to us, their options continue to vest in accordance with the original terms. Due to the change in classification of the option awards, the options are considered modified at the date of termination. The modifications are treated as exchanges of the original awards in return for the issuance of new awards. At the date of termination, the unvested options are no longer accounted for as employee awards and are accounted for as new non-employee awards. The accounting for the portion of the total grants that have already vested and have been previously expensed as equity awards is not changed. There were no employees moved to consulting status for the three months ended March 31, 2017 and 2016, respectively.

RECENT ACCOUNTING PRONOUNCEMENTS

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not applicable.

Item 4. Controls and Procedures

Disclosure Controls

We have evaluated, with the participation of our principal executive officer and our principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of March 31, 2017. Based on this evaluation, our principal executive officer and our principal financial officer have concluded that, as of March 31, 2017, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal controls over financial reporting during the three months ended March 31, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

There have been no material changes in our risk factors from those disclosed in our most recent Annual Report on Form 10-K, except for those under the subheading “Risks related to our common stock,” which section is hereby amended and restated in its entirety.

Our common stock has limited trading volume, and is therefore susceptible to high price volatility.

Our common stock is quoted on the NASDAQ Capital Market under the symbol “CATS” and has limited trading volume. As such, our common stock is susceptible to significant and sudden price changes. The liquidity of our common stock depends upon the presence in the marketplace of willing buyers and sellers. We cannot assure you that you will be able to find a buyer for your shares. We could also subsequently fail to satisfy the standards for listing on the NASDAQ Capital Market, such as standards having to do with a minimum share price, the minimum number of public shareholders or the aggregate market value of publicly held shares. Any holder of our securities should regard them as a long-term investment and should be prepared to bear the economic risk of an investment in our securities for an indefinite period.

Failure to maintain effective internal controls could adversely affect our operating results and the market for our common stock.

Section 404 of the Sarbanes-Oxley Act of 2002 requires that we maintain internal controls over financial reporting that meet applicable standards. As with many smaller companies with small staff, material weaknesses in our financial controls and procedures may be discovered. If we are unable, or are perceived as unable, to produce reliable financial reports due to internal control deficiencies, investors could lose confidence in our reported financial information and operating results, which could result in a negative market reaction and adversely affect our ability to raise capital.

We executed a reverse stock split in order to up-list to the NASDAQ Capital Market. The reduction in our outstanding shares may result in reduced liquidity for all stockholders and in increased volatility in our stock price over time.

The reduced trading volume which results from the decreased number of shares that are publically held may make it more difficult to buy or sell our stock, even though we are listed on the NASDAQ Capital Market. The reduced volume of stock trades that may result as a consequence of the reverse stock split may also increase the volatility of our stock price over time.

If we fail to comply with the continued listing requirements of the NASDAQ Capital Market, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted.

Our common stock is currently listed for trading on the NASDAQ Capital Market. We must satisfy NASDAQ’s continued listing requirements or risk delisting, which would have a material adverse effect on our business. A delisting of our common stock from the NASDAQ Capital Market could materially reduce the liquidity of our common stock and result in a corresponding material reduction in the price of our common stock. In addition, delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, suppliers, customers and employees and fewer business development opportunities.

We cannot be sure that our share price will comply with the requirements for continued listing of our common stock on the NASDAQ Capital Market in the future, or that we will comply with the other continued listing requirements. If our shares of Common Stock lose their status on the NASDAQ Capital Market, we believe that our shares of Common Stock would likely be eligible to be quoted on the OTCQB. Our shares of Common Stock may also be quoted on the Over-the-Counter Bulletin Board, an electronic quotation service maintained by the Financial Industry Regulatory Authority. These markets are generally not considered to be as efficient as, and not as broad as, the NASDAQ Capital Market. Selling our shares of Common Stock on these markets could be more difficult because smaller quantities of shares would likely be bought and sold, and transactions could be delayed. In addition, in the event our shares of Common Stock are delisted, broker-dealers have certain regulatory burdens imposed upon them, which may discourage broker-dealers from effecting transactions in our Common Stock, further limiting the liquidity of our Common Stock. These factors could result in lower prices and larger spreads in the bid and ask prices for our Common Stock.

If securities or industry analysts do not publish research or reports about us, if they change their recommendations regarding our stock adversely or if our operating results do not meet their expectations, our stock price and trading volume could decline.

The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us. If analysts do not publish research reports or one or more of these analysts who were publishing research cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. Moreover, if one or more of the analysts who cover us downgrade our stock or if our operating results do not meet their expectations, our stock price could decline.

Approximately 61% of our outstanding common stock is beneficially owned by our chairman and chief executive officer, who has the ability to substantially influence the election of directors and other matters submitted to stockholders.

10,467,797 shares are beneficially held of record by Acuitas, whose sole managing member is our Chairman and Chief Executive Officer, which represents beneficial ownership of approximately 61% of our outstanding shares of common stock. As a result, he has and is expected to continue to have the ability to significantly influence the election of our Board of Directors and the outcome of all other matters submitted to our stockholders. His interest may not always coincide with our interests or the interests of other stockholders, and he may act in a manner that advances his best interests and not necessarily those of other stockholders. One consequence to this substantial influence or control is that it may be difficult for investors to remove management of our Company. It could also deter unsolicited takeovers, including transactions in which stockholders might otherwise receive a premium for their shares over then current market prices.

Our stock price may be subject to substantial volatility, and the value of our stockholders' investment may decline.

The price at which our common stock will trade may fluctuate as a result of a number of factors, including the number of shares available for sale in the market, quarterly variations in our operating results and actual or anticipated announcements of our OnTrak solution, announcements regarding new or discontinued OnTrak solution contracts, new products or services by us or competitors, regulatory investigations or determinations, acquisitions or strategic alliances by us or our competitors, recruitment or departures of key personnel, the gain or loss of significant customers, changes in the estimates of our operating performance, actual or threatened litigation, market conditions in our industry and the economy as a whole.

Numerous factors, including many over which we have no control, may have a significant impact on the market price of our common stock, including:

	●	announcements of new products or services by us or our competitors;
	●	current events affecting the political, economic and social situation in the United States;
	●	trends in our industry and the markets in which we operate;
	●	changes in financial estimates and recommendations by securities analysts;
	●	acquisitions and financings by us or our competitors;
	●	the gain or loss of a significant customer;
	●	quarterly variations in operating results;
	●	the operating and stock price performance of other companies that investors may consider to be comparable;
	●	purchases or sales of blocks of our securities; and
	●	issuances of stock.

Furthermore, stockholders may initiate securities class action lawsuits if the market price of our stock drops significantly, which may cause us to incur substantial costs and could divert the time and attention of our management.

Future sales of common stock by existing stockholders, or the perception that such sales may occur, could depress our stock price.

The market price of our common stock could decline as a result of sales by, or the perceived possibility of sales by, our existing stockholders. We have completed a number of private placements of our common stock and other securities over the last several years, and we have effective resale registration statements pursuant to which the purchasers can freely resell their shares into the market. In addition, most of our outstanding shares are eligible for public resale pursuant to Rule 144 under the Securities Act of 1933, as amended. As of May 12, 2017, approximately 11.2 million shares of our common stock are held by our affiliates and may be sold pursuant to an effective registration statement or in accordance with the volume and other limitations of Rule 144 or pursuant to other exempt transactions. Future sales of common stock by significant stockholders, including those who acquired their shares in private placements or who are affiliates, or the perception that such sales may occur, could depress the price of our common stock.

Future issuances of common stock and hedging activities may depress the trading price of our common stock.

Any future issuance of equity securities, including upon satisfaction of our obligations, compensation of vendors, exercise of outstanding warrants, or effectuation of a stock split, could dilute the interests of our existing stockholders, and could substantially decrease the trading price of our common stock. As of May 12, 2017, we have outstanding options to purchase approximately 243,853 shares of our common stock and warrants to purchase approximately 1,921,528 shares of our common stock at prices ranging from $1.80 to $6,360.00 per share. We may issue equity securities in the future for a number of reasons, including to finance our operations and business strategy, in connection with acquisitions, to adjust our ratio of debt to equity, to satisfy our obligations upon the exercise of outstanding warrants or options or for other reasons.

There may be future sales or other dilution of our equity, which may adversely affect the market price of our common stock.

In the future, we may need to raise additional funds through public or private financing, which might include sales of equity securities. The issuance of any additional shares of common stock or securities convertible into, exchangeable for, or that represent the right to receive common stock or the exercise of such securities could be substantially dilutive to holders of shares of our common stock. Holders of shares of our common stock have no preemptive rights that entitle holders to purchase their pro rata share of any offering of shares of any class or series. The market price of our common stock could decline as a result of sales of shares of our common stock made after this offering or the perception that such sales could occur. Because our decision to issue securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of our future offerings. Thus, our stockholders bear the risk of our future offerings reducing the market price of our common stock and diluting their interests in our Company.

Provisions in our certificate of incorporation and Delaware law could discourage a change in control, or an acquisition of us by a third party, even if the acquisition would be favorable to you.

Our certificate of incorporation and the Delaware General Corporation Law contain provisions that may have the effect of making more difficult or delaying attempts by others to obtain control of our Company, even when these attempts may be in the best interests of stockholders. For example, our certificate of incorporation authorizes our Board of Directors, without stockholder approval, to issue one or more series of preferred stock, which could have voting and conversion rights that adversely affect or dilute the voting power of the holders of common stock. Delaware law also imposes conditions on certain business combination transactions with “interested stockholders.” These provisions and others that could be adopted in the future could deter unsolicited takeovers or delay or prevent changes in our control or management, including transactions in which stockholders might otherwise receive a premium for their shares over then current market prices. These provisions may also limit the ability of stockholders to approve transactions that they may deem to be in their best interests.

We do not expect to pay dividends in the foreseeable future.

We have paid no cash dividends on our common stock to date, and we intend to retain our future earnings, if any, to fund the continued development and growth of our business. As a result, we do not expect to pay any cash dividends in the foreseeable future. Further, any payment of cash dividends will also depend on our financial condition, results of operations, capital requirements and other factors, including contractual restrictions to which we may be subject, and will be at the discretion of our Board of Directors.

If persons engage in short sales of our common stock, the price of our common stock may decline.

Selling short is a technique used by a stockholder to take advantage of an anticipated decline in the price of a security. In addition, holders of options and warrants will sometimes sell short knowing they can, in effect, cover through the exercise of an option or warrant, thus locking in a profit. A significant number of short sales or a large volume of other sales within a relatively short period of time can create downward pressure on the market price of a security. Further sales of common stock issued upon exercise of our outstanding warrants could cause even greater declines in the price of our common stock due to the number of additional shares available in the market upon such exercise, which could encourage short sales that could further undermine the value of our common stock. You could, therefore, experience a decline in the value of your investment as a result of short sales of our common stock.

A number of our outstanding warrants contain anti-dilution provisions that, if triggered, could cause substantial dilution to our then-existing stockholders and adversely affect our stock price.

A number of our outstanding warrants contain anti-dilution provisions. As a result, if we, in the future, issue or grant any rights to purchase any of our common stock or other securities convertible into our common stock for a per share price less than the exercise price of our warrants, the exercise price, or in the case of some of our warrants the exercise price and number of shares of common stock, will be reduced. If our available funds and cash generated from operations are insufficient to satisfy our liquidity requirements in the future, then we may need to raise substantial additional funds in the future to support our working capital requirements and for other purposes. If shares of our common stock or securities exercisable for our common stock are issued in consideration of such funds at an effective per share price lower than our existing warrants, then the anti-dilution provisions would be triggered, thus possibly causing substantial dilution to our then-existing shareholders if such warrants are exercised. Such anti-dilution provisions may also make it more difficult for us to obtain financing.

The exercise of our outstanding warrants may result in a dilution of our current stockholders' voting power and an increase in the number of shares eligible for future resale in the public market, which may negatively impact the market price of our stock.

The exercise of some or all of our outstanding warrants could significantly dilute the ownership interests of our existing stockholders. As of May 12, 2017, we had outstanding warrants to purchase an aggregate of 1,921,528 shares of common stock at exercise prices ranging from $1.80 to $18.00 per share. To the extent warrants are exercised, additional shares of common stock will be issued, and such issuance may dilute existing stockholders and increase the number of shares eligible for resale in the public market.

In addition to the dilutive effects described above, the exercise of those warrants would lead to a potential increase in the number of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the public market could adversely affect the market price of our shares.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On January 31, 2017, we entered into a subscription agreement with Acuitas pursuant to which we received gross proceds of $1,300,000 in consideration for the issuance of (i) an 8% Series B Convertible Debenture due March 31, 2017 and ii) five-year warrants to purchase shares of the Company’s common stock in an amount equal to one hundred percent (100%) of the initial number of shares of common stock issuable upon the conversion of the convertible debenture, at an exercise price of $0.85 per share. In addition, any warrants issued in conjunction with the bridge notes currently outstanding with Acuitas were increased by an additional 25% warrant coverage. The warrants included a mechanism pursuant to which, subject to certain exempt issuances, the exercise price would be adjusted if the Company issues shares of common stock below the exercise price.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits


Exhibit 3.1	Certificate of Amendment to the Certificate of Incorporation, as amended and in effect, of Catasys, Inc., filed with the Secretary of State of Delaware on April 21, 2017, incorporated by reference to Exhibit 3.1 of Catasys, Inc.’s, Form 8-K, filed with the Securities and Exchange Commission on April 25, 2017.
Exhibit 4.1	Form of Warrant to Purchase Common Stock, incorporated by reference to Catasys, Inc.’s Form 8-K filed with the Securities and Exchange Commission on April 28, 2017.
Exhibit 31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 32.1	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Exhibit 32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*	XBRL Instance
101.SCH*	XBRL Taxonomy Extension Schema
101.CAL*	XBRL Taxonomy Extension Calculation
101.DEF*	XBRL Taxonomy Extension Definition
101.LAB*	XBRL Taxonomy Extension Labels
101.PRE*	XBRL Taxonomy Extension Presentation

* filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CATASYS, INC.
Date: May 15, 2017	By:	/s/ TERREN S. PEIZER
		Terren S. Peizer
		Chief Executive Officer (Principal Executive Officer)


Date: May 15, 2017	By:	/s/ SUSAN ETZEL
		Susan Etzel
		Chief Financial Officer (Principal Financial and Accounting Officer)

EX-31.1 2 ex31-1.htm EXHIBIT 31.1 ex31-1.htm

Exhibit 31.1

CERTIFICATION

I, Terren S. Peizer, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Catasys, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 15, 2017	/s/ TERREN S. PEIZER
	Terren S. Peizer
	Chief Executive Officer
	(Principal Executive Officer)

EX-31.2 3 ex31-2.htm EXHIBIT 31.2 ex31-2.htm

Exhibit 31.2

CERTIFICATION

I, Susan Etzel, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Catasys, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 15, 2017	/s/ SUSAN ETZEL
	Susan Etzel
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-32.1 4 ex32-1.htm EXHIBIT 32.1 ex32-1.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Catasys, Inc. (the “Company) for the quarter ended March 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report), I, Terren S. Peizer, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

	(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and

	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ TERREN S. PEIZER		May 15, 2017
Terren S. Peizer		Date
Chief Executive Officer
(Principal Executive Officer)

EX-32.2 5 ex32-2.htm EXHIBIT 32.2 ex32-2.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Catasys, Inc. (the “Company) for the quarter ended March 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report), I, Susan Etzel, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

	(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and

	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ SUSAN ETZEL		May 15, 2017
Susan Etzel		Date
Chief Financial Officer
(Principal Financial and Accounting Officer)

EX-101.INS 6 cats-20170331.xml EXHIBIT 101.INS 468750 0.25 0.25 1.25 0.20 1 0.75 0.75 1 0.25 100 3 2 10000000 10596000 1337000 -926000 14800000 4.464 12893000 12893000 5307000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Warrant Liabilities</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">       In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> we entered into a Subscription Agreement (the “Subscription Agreement”) with Acuitas Group Holdings, LLC (“Acuitas”), <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> hundred percent <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(100%)</div> of which is owned by Terren S. Peizer, Chairman and Chief Executive Officer of the Company, pursuant to which we will receive aggregate gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,300,000</div> (the “Loan Amount”) in consideration of the issuance of (i) an <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8%</div> Series B Convertible Debenture due <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> “January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Convertible Debenture”) and (ii) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div>-year warrants to purchase shares of the Company’s common stock in an amount equal to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> hundred percent <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(100%)</div> of the initial number of shares of common stock issuable upon the conversion of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Convertible Debenture, at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.10</div> per share (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> “January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Warrants”). The Loan Amount is payable in tranches through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> and as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> we have received <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,115,000.</div> In addition, any warrants issued in conjunction with the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Convertible Debenture currently outstanding with Acuitas have been increased by an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25%</div> warrant coverage, exercisable for an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">137,883</div> shares of the Company’s common stock. Acuitas agreed to extend the maturity date of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Convertible Debenture to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> or until we complete a public offering, whichever comes <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first.</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">       The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Warrants include, among other things, price protection provisions pursuant to which, subject to certain exempt issuances, the then exercise price of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Warrants will be adjusted if the Company issues shares of common stock at a price that is less than the then exercise price of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Warrants. Such price protection provisions will remain in effect until the earliest of (i) the termination date of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Warrants, (ii) such time as the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Warrants are exercised or (iii) contemporaneously with the listing of the Company’s shares of common stock on a registered national securities exchange.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">       In connection with the Subscription Agreement described above, the number of Shamus warrants issued as part of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Convertible Debenture were increased from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">75%</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100%</div> warrant coverage, exercisable for an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">58,824</div> shares of the Company’s common stock.</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div> </div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">       The warrant liabilities were calculated using the Black-Scholes model based upon the following assumptions:</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div> </div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 90%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 83%" width="921"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%" width="8"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; WIDTH: 10%" colspan="3" width="161"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">March 31, 201</div><div style="display: inline; font-weight: bold;">7</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; WIDTH: 1%" width="12"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 83%; BACKGROUND-COLOR: #cceeff" width="921"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected volatility</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" width="8"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 5%; BACKGROUND-COLOR: #cceeff" width="78"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; WIDTH: 5%; BACKGROUND-COLOR: #cceeff" width="78"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">93.56%</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 5%; BACKGROUND-COLOR: #cceeff" width="83"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap" width="12"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div> </div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 83%; BACKGROUND-COLOR: #ffffff" width="921"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Risk-free interest rate</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" width="8"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 5%; BACKGROUND-COLOR: #ffffff" width="78"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.27</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; WIDTH: 5%; BACKGROUND-COLOR: #ffffff" width="78"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; WIDTH: 5%; BACKGROUND-COLOR: #ffffff" width="83"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.93%</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap" width="12"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div> </div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 83%; BACKGROUND-COLOR: #cceeff" width="921"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Weighted average expected lives in years</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" width="8"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 5%; BACKGROUND-COLOR: #cceeff" width="78"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> 2</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; WIDTH: 5%; BACKGROUND-COLOR: #cceeff" width="78"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; WIDTH: 5%; BACKGROUND-COLOR: #cceeff" width="83"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap" width="12"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 83%; BACKGROUND-COLOR: #ffffff" width="921"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected dividend</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" width="8"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 5%; BACKGROUND-COLOR: #ffffff" width="78"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; WIDTH: 5%; BACKGROUND-COLOR: #ffffff" width="78"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0%</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 5%; BACKGROUND-COLOR: #ffffff" width="83"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap" width="12"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div> </div></td> </tr> </table> </div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We have issued warrants to purchase common stock in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2012,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> The warrants are being accounted for as liabilities in accordance with FASB accounting rules, due to anti-dilution provisions in some warrants that protect the holders from declines in our stock price, which is considered outside our control.  The warrants are marked-to-market each reporting period, using the Black-Scholes pricing model, until they are completely settled or expire.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">For the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> we recognized a loss of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.2</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$228,000,</div> respectively, related to the revaluation of our warrant liabilities.</div></div></div></div></div></div></div> P5Y 32400000 false --12-31 Q1 2017 2017-03-31 10-Q 0001136174 15874678 Yes Smaller Reporting Company CATASYS, INC. No No cats

1221000

870000

1660000

1620000

256881000

254385000

149000

2622000

216000

1928431

620119

2940000

3104000

2150000

2323000

106000

22000

31000

851000

916000

291000

262000

106000

-560000

-654000

291000

115038

5.10

137883

58824

137883

14706

11049

156250

0.0001

500000000

9443749

9214743

9443749

9214743

6000

0.94

0.79

1365000

966000

214514

1300000

11.40

1.80

3550000

0.08

0.12

216000

95000

117000

1943000

1525000

39000

32000

39000

32000

-5200000

-228000

18718000

8122000

18718000

204000

1100000

10046000

9796000

-2.35

-0.47

2020000

2089000

191000

P1Y189D

5181000

228000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 90%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 83%; VERTICAL-ALIGN: bottom" width="921"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom" width="8"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; MARGIN-LEFT: 0pt" width="161" colspan="3"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">March 31, 201</div><div style="display: inline; font-weight: bold;">7</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px" width="12"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 83%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="921"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected volatility</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="8"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="78"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff" width="78"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">93.56%</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="83"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="12" nowrap="nowrap"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div> </div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 83%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="921"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Risk-free interest rate</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="8"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="78"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.27</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff" width="78"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="83"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.93%</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="12" nowrap="nowrap"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div> </div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 83%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="921"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Weighted average expected lives in years</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="8"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="78"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> 2</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff" width="78"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="83"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="12" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 83%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="921"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected dividend</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="8"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="78"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff" width="78"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0%</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="83"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="12" nowrap="nowrap"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div> </div></td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 90%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">March 31, 201</div><div style="display: inline; font-weight: bold;">7</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 83%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected volatility</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">93.56</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">%</div></div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Risk-free interest rate</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.74</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">%</div></div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Weighted average expected lives in years</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.08</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected dividend</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">%</div></div></td> </tr> </table></div>

P2Y

P5Y

P29D

0.9356

0.0127

0.0193

0.0074

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Level III</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Level III</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Warrant </div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Derivative </div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">(Dollars in thousands)</div></div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Liabilities</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">(Dollars in thousands)</div></div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Liabilities</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance as of December 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,307 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance as of December 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,122 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Issuance of warrants</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,405 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Issuance of warrants</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Change in fair value </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,181 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Change in fair value </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,596 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance as of March 31, 2017</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,893 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance as of March 31, 2017</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,718 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="WIDTH: 37%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 12%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 36%; BACKGROUND-COLOR: #cceeff" colspan="2"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 10%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 0%; BACKGROUND-COLOR: #cceeff"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Issuance (exercise) of warrants, net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Issuance (exercise) of warrants, net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Change in fair value</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Change in fair value</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance as of June 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,893 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance as of June 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,718 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="WIDTH: 37%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 12%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 36%; BACKGROUND-COLOR: #cceeff" colspan="2"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 10%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 0%; BACKGROUND-COLOR: #cceeff"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Issuance (exercise) of warrants, net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Issuance (exercise) of warrants, net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expiration of warrants</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expiration of warrants</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Change in fair value</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Change in fair value</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance as of September 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,893 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance as of September 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,718 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> </table></div>

5181000

10596000

2405000

5307000

8122000

12893000

18718000

12893000

18718000

12893000

18718000

10600000

1300000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Fair Value Measurements</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure fair value. The fair value hierarchy distinguishes between <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1)</div> market participant assumptions developed based on market data obtained from independent sources (observable inputs) and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2)</div> an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level I) and the lowest priority to unobservable inputs (Level III). The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> levels of the fair value hierarchy are described below:</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 84.6%; TEXT-INDENT: 0px;" align="center" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 16.1%"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Level Input:</div></div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 3.5%">  </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 80.4%"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Input Definition:</div></div></div></td> </tr> <tr> <td style="VERTICAL-ALIGN: top; WIDTH: 16.1%"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level I</div></div></td> <td style="VERTICAL-ALIGN: top; WIDTH: 3.5%">  </td> <td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px; WIDTH: 80.4%"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.</div></div></td> </tr> <tr> <td style="VERTICAL-ALIGN: top; WIDTH: 16.1%"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level II</div></div></td> <td style="VERTICAL-ALIGN: top; WIDTH: 3.5%">  </td> <td style="VERTICAL-ALIGN: top; WIDTH: 80.4%"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.</div></div></td> </tr> <tr> <td style="VERTICAL-ALIGN: top; WIDTH: 16.1%"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level III</div></div></td> <td style="VERTICAL-ALIGN: top; WIDTH: 3.5%">  </td> <td style="VERTICAL-ALIGN: top; WIDTH: 80.4%"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.</div></div></td> </tr> </table> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following table summarizes fair value measurements by level at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> for assets and liabilities measured at fair value:</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 22pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 10%; WIDTH: 80%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="14"><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;"></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Balance at March 31, 2017</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 36%"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">(Amounts in thousands)</div></div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Level I</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Level II</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Level III</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Total</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Certificates of deposit</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 13%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 13%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 13%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 13%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total assets </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 13%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 13%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 13%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 13%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Warrant liabilities</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 13%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 13%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 13%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,893 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 13%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,893 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Derivative Liability</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 13%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,718 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 13%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,718 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total liabilities </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 13%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 13%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 13%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,611 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 13%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,611 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div> </div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Carrying amounts reported in the condensed consolidated balance sheets of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate fair value due to their relatively short maturity. The fair value of borrowings is not considered to be significantly different from its carrying amount because stated rates for such debt reflect current market rates and conditions.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Financial instruments classified as Level III in the fair value hierarchy as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> represent our liabilities measured at market value on a recurring basis which include warrant liabilities and derivative liabilities resulting from recent debt and equity financings. In accordance with current accounting rules, the warrant liabilities and derivative liabilities are being marked-to-market each quarter-end until they are completely settled or expire. The warrants and derivative liabilities are valued using the Black-Scholes option-pricing model, using both observable and unobservable inputs and assumptions consistent with those used in our estimate of fair value of employee stock options. See <div style="display: inline; font-style: italic;">Warrant Liabilities</div> below. </div></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></div> </div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"></div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following table summarizes our fair value measurements using significant Level III inputs, and changes therein, for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017:</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; WIDTH: 1%" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Level III</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; WIDTH: 1%" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Level III</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; WIDTH: 1%" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Warrant </div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; WIDTH: 1%" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Derivative </div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 37%"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">(Dollars in thousands)</div></div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Liabilities</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px; WIDTH: 1%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 36%"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">(Dollars in thousands)</div></div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Liabilities</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px; WIDTH: 0%"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 37%; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance as of December 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,307 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 36%; BACKGROUND-COLOR: #cceeff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance as of December 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 10%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,122 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 0%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-LEFT: 9pt; WIDTH: 37%; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Issuance of warrants</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,405 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-LEFT: 9pt; WIDTH: 36%; BACKGROUND-COLOR: #ffffff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Issuance of warrants</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 10%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 0%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-LEFT: 9pt; WIDTH: 37%; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Change in fair value </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,181 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-LEFT: 9pt; WIDTH: 36%; BACKGROUND-COLOR: #cceeff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Change in fair value </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 10%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,596 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 0%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 37%; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance as of March 31, 2017</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,893 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 36%; BACKGROUND-COLOR: #ffffff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance as of March 31, 2017</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 10%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,718 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 0%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="WIDTH: 37%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 12%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 36%; BACKGROUND-COLOR: #cceeff" colspan="2"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 10%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 0%; BACKGROUND-COLOR: #cceeff"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-LEFT: 9pt; WIDTH: 37%; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Issuance (exercise) of warrants, net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-LEFT: 9pt; WIDTH: 36%; BACKGROUND-COLOR: #ffffff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Issuance (exercise) of warrants, net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 10%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 0%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-LEFT: 9pt; WIDTH: 37%; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Change in fair value</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-LEFT: 9pt; WIDTH: 36%; BACKGROUND-COLOR: #cceeff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Change in fair value</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 10%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 0%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 37%; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance as of June 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,893 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 36%; BACKGROUND-COLOR: #ffffff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance as of June 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 10%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,718 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 0%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="WIDTH: 37%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 12%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 36%; BACKGROUND-COLOR: #cceeff" colspan="2"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 10%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 0%; BACKGROUND-COLOR: #cceeff"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-LEFT: 9pt; WIDTH: 37%; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Issuance (exercise) of warrants, net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-LEFT: 9pt; WIDTH: 36%; BACKGROUND-COLOR: #ffffff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Issuance (exercise) of warrants, net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 10%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 0%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-LEFT: 9pt; WIDTH: 37%; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expiration of warrants</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-LEFT: 9pt; WIDTH: 36%; BACKGROUND-COLOR: #cceeff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expiration of warrants</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 10%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 0%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-LEFT: 9pt; WIDTH: 37%; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Change in fair value</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-LEFT: 9pt; WIDTH: 36%; BACKGROUND-COLOR: #ffffff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Change in fair value</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 10%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 0%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 37%; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance as of September 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,893 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 36%; BACKGROUND-COLOR: #cceeff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance as of September 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 10%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,718 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 0%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> </table> </div></div></div></div></div></div>

-10596000

-1337000

2629000

2187000

1822000

728000

-21767000

-4290000

2000

39000

26000

534000

96000

360000

27000

418000

593000

-20000

-23000

176000

-141000

14000

65000

2867000

333000

117000

47540000

28432000

2940000

3104000

34530000

22977000

31611000

1104000

858000

-49000

6000

-1615000

-1518000

-21768000

-4292000

4033000

3185000

-2211000

-2457000

582000

575000

371000

-16000

49000

10000

0.0001

50000000

596000

420000

16500000

1300000

1115000

1300000

1115000

900000

419000

410000

P2Y

P7Y

P5Y

P7Y

149000

7000

1263000

1052000

11000

42000

-301487000

-279719000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="14"><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;"></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Balance at March 31, 2017</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; VERTICAL-ALIGN: bottom"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">(Amounts in thousands)</div></div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Level I</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Level II</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Level III</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Total</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Certificates of deposit</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total assets </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Warrant liabilities</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,893 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,893 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Derivative Liability</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,718 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,718 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total liabilities </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,611 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,611 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> </table></div>

127000

174000

127000

174000

127000

174000

P3Y

P5Y

2333334

50774

244000

39.06

38.90

243853

P10Y

4.80

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div> Summary of Significant Accounting Policies</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Revenue Recognition</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">        Our Catasys contracts are generally designed to provide cash fees to us on a monthly basis or an upfront case rate based on enrolled members. To the extent our contracts <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> include a minimum performance guarantee; we reserve a portion of the fees that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> be at risk until the performance measurement period is completed. To the extent we receive case rates or other fees in advance that are not subject to the performance guarantees, we recognize the case rate ratably over the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months of our program. We recognize any fees from sharing in the savings generated from enrolled members when we receive payment.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Cost of Services</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cost of healthcare services consists primarily of salaries related to our care coaches, outreach specialists and other staff directly involved in member care, healthcare provider claims payments, and fees charged by our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> party administrators for processing these claims. Salaries and fees charged by our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> party administrators for processing claims are expensed when incurred and healthcare provider claims payments are recognized in the period in which an eligible member receives services. We contract with doctors and licensed behavioral healthcare professionals, on a fee-for-service basis. We determine that a member has received services when we receive a claim or in the absence of a claim, by utilizing member data recorded in the eOn<div style="display: inline; font-style: italic;">Trak</div><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline; vertical-align: baseline; position: relative; bottom:.33em;">TM </div>database within the contracted timeframe, with all required billing elements correctly completed by the service provider.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></div> </div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Cash Equivalents and Concentration of Credit Risk</div><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We consider all highly liquid investments with an original maturity of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months or less to be cash equivalents. Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Cash is deposited with what we believe are highly credited, quality financial institutions. The deposited cash <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> exceed Federal Deposit Insurance Corporation (“FDIC”) insured limits. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> cash and cash equivalents exceeding federally insured limits totaled <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$115,038.</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">For the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> customers accounted for approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">94%</div> of revenues and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> customers accounted for approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">79%</div> of accounts receivable. </div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Basic and Diluted </div><div style="display: inline; font-weight: bold;">Income (Loss) per Share</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Basic income (loss) per share is computed by dividing the net income (loss) to common stockholders for the period by the weighted average number of common stock outstanding during the period. Diluted income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of common stock and dilutive common equivalent shares outstanding during the period.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Common equivalent shares, consisting of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,928,431</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">620,119</div> common shares for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively, issuable upon the exercise of stock options and warrants have been excluded from the diluted earnings per share calculation as their effect is anti-dilutive. </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Share-Based Compensation</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Stock Incentive Plan (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">“2017</div> Plan”), provides for the issuance of up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,333,334</div> shares of our common stock. Incentive stock options (ISOs) under Section <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">422A</div> of the Internal Revenue Code and non-qualified options (NSOs) are authorized under the Plan. We have granted stock options to executive officers, employees, members of our board of directors, and certain outside consultants. The terms and conditions upon which options become exercisable vary among grants, but option rights expire no later than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div> years from the date of grant and employee and board of director awards generally vest over <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> years. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> we had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">243,853</div> vested and unvested shares outstanding and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50,774</div> shares available for future awards under the Plan.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total share-based compensation expense on a consolidated basis was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$127,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$174,000</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"> </div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Stock Options – Employees and Directors</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We measure and recognize compensation expense for all share-based payment awards made to employees and directors based on estimated fair values on the date of grant. We estimate the fair value of share-based payment awards using the Black-Scholes option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the consolidated statements of operations.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Share-based compensation expense recognized for employees and directors for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$127,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$174,000,</div> respectively.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">For share-based awards issued to employees and directors, share-based compensation is attributed to expense using the straight-line single option method. Share-based compensation expense recognized in our consolidated statements of operations for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> is based on awards ultimately expected to vest, reduced for estimated forfeitures. Accounting rules for stock options require forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></div> </div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no </div></div>options granted to employees and directors during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively, under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Plan. Employee and director stock option activity for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> are as follows:</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: center"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Weighted Avg.</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Shares</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Exercise Price</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance December 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">244,000 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39.06 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Granted</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cancelled</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance March 31, 2017</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">244,000 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38.90 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The expected volatility assumptions have been based on the historical and expected volatility of our stock, measured over a period generally commensurate with the expected term. The weighted average expected option term for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> reflects the application of the simplified method prescribed in SEC Staff Accounting Bulletin (“SAB”) No. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">107</div> (as amended by SAB <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">110),</div> which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> there was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$191,000</div> of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plan. That cost is expected to be recognized over a weighted-average period of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.52</div> years.</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">          </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Stock Options and Warrants – Non-employees</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We account for the issuance of options and warrants for services from non-employees by estimating the fair value of warrants issued using the Black-Scholes pricing model. This model’s calculations include the option or warrant exercise price, the market price of shares on grant date, the weighted average risk-free interest rate, the expected life of the option or warrant, and the expected volatility of our stock and the expected dividends.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">For options and warrants issued as compensation to non-employees for services that are fully vested and non-forfeitable at the time of issuance, the estimated value is recorded in equity and expensed when the services are performed and benefit is received. For unvested shares, the change in fair value during the period is recognized in expense using the graded vesting method.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no </div></div>options issued to non-employees for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively. There was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no </div></div>share-based compensation expense relating to stock options and warrants recognized for the non-employees for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Common Stock</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,492</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0</div> shares of common stock issued in exchange for investor relations services during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively. Generally, the costs associated with shares issued for services are amortized to the related expense on a straight-line basis over the related service periods. </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">214,514</div> shares of common stock issued to Shamus, LLC (“Shamus”), </div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">a Company owned by David E. Smith, a member of our board of directors for the conversion of their <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Convertible Debentures.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Income Taxes</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We have recorded a full valuation allowance against our otherwise recognizable deferred tax assets as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div>  As such, we have <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not </div>recorded a provision for income tax for the period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div>  We utilize the liability method of accounting for income taxes as set forth in ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">740,</div> Income Taxes. Under the liability method, deferred taxes are determined based on the temporary differences between the financial statement and tax basis of assets and liabilities using tax rates expected to be in effect during the years in which the basis differences reverse. A valuation allowance is recorded when it is more likely than not that some of the deferred tax assets will not be realized. </div></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></div> </div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We assess our income tax positions and record tax benefits for all years subject to examination based upon our evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where there is greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50%</div> likelihood that a tax benefit will be sustained, we have recorded the largest amount of tax benefit that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> potentially be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is less than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50%</div> likelihood that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements.  Based on management's assessment of the facts, circumstances and information available, management has determined that all of the tax benefits for the period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> should be realized.   </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Fair Value Measurements</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure fair value. The fair value hierarchy distinguishes between <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1)</div> market participant assumptions developed based on market data obtained from independent sources (observable inputs) and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2)</div> an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level I) and the lowest priority to unobservable inputs (Level III). The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> levels of the fair value hierarchy are described below:</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 84.6%; TEXT-INDENT: 0px;" cellspacing="0" cellpadding="0" border="0" align="center"> <tr> <td style="WIDTH: 16.1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Level Input:</div></div></div></td> <td style="WIDTH: 3.5%; VERTICAL-ALIGN: bottom">  </td> <td style="WIDTH: 80.4%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Input Definition:</div></div></div></td> </tr> <tr> <td style="WIDTH: 16.1%; VERTICAL-ALIGN: top"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level I</div></div></td> <td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">  </td> <td style="WIDTH: 80.4%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.</div></div></td> </tr> <tr> <td style="WIDTH: 16.1%; VERTICAL-ALIGN: top"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level II</div></div></td> <td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">  </td> <td style="WIDTH: 80.4%; VERTICAL-ALIGN: top"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.</div></div></td> </tr> <tr> <td style="WIDTH: 16.1%; VERTICAL-ALIGN: top"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level III</div></div></td> <td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">  </td> <td style="WIDTH: 80.4%; VERTICAL-ALIGN: top"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.</div></div></td> </tr> </table> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following table summarizes fair value measurements by level at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> for assets and liabilities measured at fair value:</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 22pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="14"><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;"></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Balance at March 31, 2017</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; VERTICAL-ALIGN: bottom"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">(Amounts in thousands)</div></div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Level I</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Level II</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Level III</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Total</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Certificates of deposit</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total assets </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> <td style="BACKGROUND-COLOR: #cceeff"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Warrant liabilities</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,893 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,893 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Derivative Liability</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,718 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,718 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total liabilities </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,611 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,611 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div> </div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Carrying amounts reported in the condensed consolidated balance sheets of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate fair value due to their relatively short maturity. The fair value of borrowings is not considered to be significantly different from its carrying amount because stated rates for such debt reflect current market rates and conditions.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Financial instruments classified as Level III in the fair value hierarchy as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> represent our liabilities measured at market value on a recurring basis which include warrant liabilities and derivative liabilities resulting from recent debt and equity financings. In accordance with current accounting rules, the warrant liabilities and derivative liabilities are being marked-to-market each quarter-end until they are completely settled or expire. The warrants and derivative liabilities are valued using the Black-Scholes option-pricing model, using both observable and unobservable inputs and assumptions consistent with those used in our estimate of fair value of employee stock options. See <div style="display: inline; font-style: italic;">Warrant Liabilities</div> below. </div></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"> </div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following table summarizes our fair value measurements using significant Level III inputs, and changes therein, for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017:</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Level III</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Level III</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Warrant </div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Derivative </div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">(Dollars in thousands)</div></div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Liabilities</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">(Dollars in thousands)</div></div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Liabilities</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance as of December 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,307 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance as of December 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,122 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Issuance of warrants</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,405 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Issuance of warrants</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Change in fair value </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,181 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Change in fair value </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,596 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance as of March 31, 2017</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,893 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance as of March 31, 2017</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,718 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="WIDTH: 37%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 12%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 36%; BACKGROUND-COLOR: #cceeff" colspan="2"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 10%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 0%; BACKGROUND-COLOR: #cceeff"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Issuance (exercise) of warrants, net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Issuance (exercise) of warrants, net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Change in fair value</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Change in fair value</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance as of June 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,893 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance as of June 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,718 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="WIDTH: 37%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 12%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 36%; BACKGROUND-COLOR: #cceeff" colspan="2"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 10%; BACKGROUND-COLOR: #cceeff"> </td> <td style="WIDTH: 0%; BACKGROUND-COLOR: #cceeff"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Issuance (exercise) of warrants, net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Issuance (exercise) of warrants, net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expiration of warrants</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expiration of warrants</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Change in fair value</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Change in fair value</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 37%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance as of September 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,893 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" colspan="2"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance as of September 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,718 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Property and Equipment</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"> </div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Property and equipment are stated at cost, less accumulated depreciation. Additions and improvements to property and equipment are capitalized at cost. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, which range from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">seven</div> years for furniture and equipment. Leasehold improvements are amortized over the lesser of the estimated useful lives of the assets or the related lease term, which is typically <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">seven</div> years. </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Warrant Liabilities</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">       In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> we entered into a Subscription Agreement (the “Subscription Agreement”) with Acuitas Group Holdings, LLC (“Acuitas”), <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> hundred percent <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(100%)</div> of which is owned by Terren S. Peizer, Chairman and Chief Executive Officer of the Company, pursuant to which we will receive aggregate gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,300,000</div> (the “Loan Amount”) in consideration of the issuance of (i) an <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8%</div> Series B Convertible Debenture due <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> “January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Convertible Debenture”) and (ii) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div>-year warrants to purchase shares of the Company’s common stock in an amount equal to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> hundred percent <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(100%)</div> of the initial number of shares of common stock issuable upon the conversion of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Convertible Debenture, at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.10</div> per share (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> “January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Warrants”). The Loan Amount is payable in tranches through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> and as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> we have received <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,115,000.</div> In addition, any warrants issued in conjunction with the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Convertible Debenture currently outstanding with Acuitas have been increased by an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25%</div> warrant coverage, exercisable for an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">137,883</div> shares of the Company’s common stock. Acuitas agreed to extend the maturity date of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Convertible Debenture to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> or until we complete a public offering, whichever comes <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first.</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">       The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Warrants include, among other things, price protection provisions pursuant to which, subject to certain exempt issuances, the then exercise price of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Warrants will be adjusted if the Company issues shares of common stock at a price that is less than the then exercise price of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Warrants. Such price protection provisions will remain in effect until the earliest of (i) the termination date of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Warrants, (ii) such time as the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Warrants are exercised or (iii) contemporaneously with the listing of the Company’s shares of common stock on a registered national securities exchange.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">       In connection with the Subscription Agreement described above, the number of Shamus warrants issued as part of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Convertible Debenture were increased from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">75%</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100%</div> warrant coverage, exercisable for an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">58,824</div> shares of the Company’s common stock.</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">       The warrant liabilities were calculated using the Black-Scholes model based upon the following assumptions:</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div> </div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 90%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 83%; VERTICAL-ALIGN: bottom" width="921"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom" width="8"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; MARGIN-LEFT: 0pt" colspan="3" width="161"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">March 31, 201</div><div style="display: inline; font-weight: bold;">7</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px" width="12"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 83%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="921"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected volatility</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="8"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="78"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff" width="78"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">93.56%</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="83"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="12" nowrap="nowrap"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div> </div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 83%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="921"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Risk-free interest rate</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="8"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="78"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.27</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff" width="78"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="83"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.93%</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="12" nowrap="nowrap"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div> </div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 83%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="921"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Weighted average expected lives in years</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="8"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="78"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> 2</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff" width="78"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="83"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="12" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 83%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="921"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected dividend</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="8"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="78"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff" width="78"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0%</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="83"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="12" nowrap="nowrap"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div> </div></td> </tr> </table> </div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We have issued warrants to purchase common stock in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2012,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> The warrants are being accounted for as liabilities in accordance with FASB accounting rules, due to anti-dilution provisions in some warrants that protect the holders from declines in our stock price, which is considered outside our control.  The warrants are marked-to-market each reporting period, using the Black-Scholes pricing model, until they are completely settled or expire.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">For the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> we recognized a loss of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.2</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$228,000,</div> respectively, related to the revaluation of our warrant liabilities.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Derivative Liability</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> we entered into a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.55</div> million <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12%</div> Original Issue Discount Convertible Debenture due <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> with Acuitas (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> “July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> Convertible Debenture”). The conversion price of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> Convertible Debenture is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$11.40</div> per share, subject to adjustments, including for issuances of common stock and common stock equivalents below the then current conversion or exercise price, as the case <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> be.  In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> we entered into an amendment of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> Convertible Debenture which extended the maturity date of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> Convertible Debenture from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> In addition, the conversion price of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> Convertible Debenture was subsequently adjusted to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.80</div> per share. The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> Convertible Debenture is unsecured, bears interest at a rate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12%</div> per annum payable in cash or shares of common stock, subject to certain conditions, at our option, and is subject to mandatory prepayment upon the consummation of certain future financings. Acuitas agreed to extend the maturity date of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> Convertible Debenture to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> or until we complete a public offering, whichever comes <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first.</div> The derivative liability associated with the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> Convertible Debenture was calculated using the Black-Scholes model based upon the following assumptions: </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 90%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">March 31, 201</div><div style="display: inline; font-weight: bold;">7</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 83%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected volatility</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">93.56</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">%</div></div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Risk-free interest rate</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.74</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">%</div></div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Weighted average expected lives in years</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.08</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected dividend</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">%</div></div></td> </tr> </table> </div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">For the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> we recognized a loss of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10.6</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.3</div> million related to the revaluation of our derivative liability, respectively.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Recently Issued or Newly Adopted Accounting Standards</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the FASB issued Accounting Standards Update (“ASU”) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,</div> <div style="display: inline; font-style: italic;">Revenue from Contracts with Customers (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606)</div></div>, which amends certain aspects of the Board’s new revenue standard, ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div> Revenue from Contracts with Customers. The standard should be adopted concurrently with adoption of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div> which is effective for annual and interim periods beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> Early adoption is permitted. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div> <div style="display: inline; font-style: italic;">Compensation — Stock Compensation (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718):</div> Improvements to Employee Share-Based Payment Accounting </div>(“ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09”),</div> which outlines new provisions intended to simplify various aspects related to accounting for share-based payments and their presentation in the financial statements. The standard is effective for the Company for fiscal years beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> and interim periods within those annual periods. Early adoption is permitted. The adoption of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> did not have a material effect on our consolidated financial positon or results of operations. </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> the FASB issued ASU, <div style="display: inline; font-style: italic;">Consolidation (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">810):</div> Amendments to the Consolidation Analysis</div> (“ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02”).</div> ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> modifies existing consolidation guidance for reporting organizations that are required to evaluate whether they should consolidate certain legal entities. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> is effective for fiscal years and interim periods within those years beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> and requires either a retrospective or a modified retrospective approach to adoptions. The adoption of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> did not have a material effect on our consolidated financial position or results of operations. </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> the FASB issued FASB ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> <div style="display: inline; font-style: italic;">Presentation of Financial Statements—Going Concern (Subtopic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">205</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40):</div> Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern </div>(“ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15”)</div><div style="display: inline; font-style: italic;">. </div>ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div> changes the disclosure of uncertainties about an entity’s ability to continue as a going concern. Under U.S. GAAP, continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Even if an entity’s liquidation is not imminent, there <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. Because there is no guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related note disclosures, there is diversity in practice whether, when, and how an entity discloses the relevant conditions and events in its financial statements. As a result, these changes require an entity’s management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year after the date that financial statements are issued. Substantial doubt is defined as an indication that it is probable that an entity will be unable to meet its obligations as they become due within <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year after the date that financial statements are issued. If management has concluded that substantial doubt exists, then the following disclosures should be made in the financial statements: (i) principal conditions or events that raised the substantial doubt, (ii) management’s evaluation of the significance of those conditions or events in relation to the entity’s ability to meet its obligations, (iii) management’s plans that alleviated the initial substantial doubt or, if substantial doubt was not alleviated, management’s plans that are intended to at least mitigate the conditions or events that raise substantial doubt, and (iv) if the latter in (iii) is disclosed, an explicit statement that there is substantial doubt about the entity’s ability to continue as a going concern. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div> is effective for periods beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div> The adoption of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div> did not have a material effect on our consolidated position or results of operations.</div></div></div>

117000

14492

3125000

303750

-44600000

-25328000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.</div> Subsequent Event</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"></div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Amendments to Outstanding Warrants and Extension of Existing Debentures</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> we entered into amendments with the holders of certain outstanding warrants issued on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> to eliminate certain anti-dilution provisions in such warrants, which caused us to reflect an associated liability of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$12.8</div> million on our balance sheet as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> Such amendments did not take effect until <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">28,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div>  For each warrant share underlying the warrants so amended, the holder received the right to purchase an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.2</div> shares of common stock. Two of the holders of such warrants, which owners hold warrants to purchase an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,049</div> shares of common stock, did not agree to the amendment. The warrant holders agreeing to the amendment include Acuitas and another accredited investor.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Additionally, in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> we and the holders of an aggregate of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10</div> million of our existing convertible debentures agreed to extend the maturity dates of such debentures until <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">28,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"> </div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Reverse Stock Split</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> we filed a certificate of amendment to our Certificate of Incorporation, as amended and in effect, with the Secretary of State of the State of Delaware, implementing a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>-for-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div> reverse stock split of the Company's common stock, pursuant to which each <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> shares of issued and outstanding common stock converted into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> share of common stock. Proportionate voting rights and other rights of common stock holders will not be affected by the reverse stock split.  No fractional shares of common stock were issued as a result of the reverse stock split; stockholders were paid cash in lieu of any such fractional shares. The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>-for-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div> reverse stock split became effective at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5:00</div> p.m., Eastern Time, on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> and our common stock began trading on the OTCQB Marketplace on a post-split basis at the open of trading on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> Our post-reverse split common stock has a new CUSIP number: <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">149049</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">504.</div> Other terms of the common stock are not affected by the reverse stock split.  The common stock will continue to trade under the symbol "CATS." </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">All stock options and warrants to purchase common stock outstanding and our Common Stock reserved for issuance under the Company's equity incentive plans immediately prior to the reverse stock split were appropriately adjusted by dividing the number of affected shares of common stock by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> and, as applicable, multiplying the exercise price by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> as a result of the reverse stock split.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Public Offering</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> we entered into an underwriting agreement with Joseph Gunnar & Co., LLC, as underwriter in connection with a public offering of the Company’s securities. Pursuant to the underwriting agreement, we agreed to issue and sell an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,125,000</div> shares of Common Stock at a public offering price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.80</div> per share, and the purchase price to the underwriter after discounts and commissions was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.464</div> per share. The closing of the offering occurred on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">28,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> The Company received <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$14.8</div> million in net proceeds in connection with this offering.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pursuant to the underwriting agreement, we issued to the underwriter a warrant for the purchase of an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">156,250</div> shares of Common Stock for an aggregate purchase price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$100.</div> The exercise price of the warrant is equal to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">125%</div> of the public offering price in the offering, or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6.00</div> per share of Common Stock.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"> </div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">NASDAQ Uplisting</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In connection with the public offering, our Common Stock began trading on the NASDAQ Capital Market under the symbol “CATS” beginning on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Exercise of Over-Allotment Option</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pursuant to the underwriting with Joseph Gunnar & Co., LLC dated <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> we agreed to issue to the underwriters a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">45</div>-day over-allotment option to purchase up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">468,750</div> additional shares of Common Stock at the public offering price less the applicable underwriter discount. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> the underwriter acquired an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">303,750</div> shares pursuant to such over-allotment option. </div></div></div>

9246000

9168000

xbrli:shares xbrli:pure iso4217:USD iso4217:USD xbrli:shares 0001136174 2016-01-01 2016-03-31 0001136174 cats:CommonStockIssuedForInvestorRelationServicesMember 2016-01-01 2016-03-31 0001136174 cats:TwentySeventeenStockIncentivePlanMember 2016-01-01 2016-03-31 0001136174 cats:TwentySeventeenStockIncentivePlanMember cats:EmployeesAndDirectorsMember 2016-01-01 2016-03-31 0001136174 cats:TwentySeventeenStockIncentivePlanMember cats:NonemployeesMember 2016-01-01 2016-03-31 0001136174 cats:EmployeesAndDirectorsMember 2016-01-01 2016-03-31 0001136174 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2016-07-01 2016-09-30 0001136174 us-gaap:FairValueInputsLevel3Member cats:WarrantsMember 2016-07-01 2016-09-30 0001136174 cats:December2016WarrantsMember cats:AcuitasMember 2017-01-01 2017-01-31 0001136174 cats:December2016WarrantsMember cats:AcuitasMember 2017-01-01 2017-01-31 0001136174 cats:January2017WarrantsMember cats:AcuitasMember 2017-01-01 2017-01-31 0001136174 cats:AcuitasMember cats:January2017ConvertibleDebentureMember 2017-01-01 2017-01-31 0001136174 cats:AcuitasMember cats:January2017ConvertibleDebentureMember 2017-01-01 2017-01-31 0001136174 2017-01-01 2017-03-31 0001136174 cats:CommonStockIssuedForInvestorRelationServicesMember 2017-01-01 2017-03-31 0001136174 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember cats:TwoCustomersMember 2017-01-01 2017-03-31 0001136174 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember cats:ThreeCustomersMember 2017-01-01 2017-03-31 0001136174 cats:ConversionOfDecember2016ConvertibleDebenturesIntoCommonStockMember cats:ShamusMember 2017-01-01 2017-03-31 0001136174 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2017-01-01 2017-03-31 0001136174 us-gaap:FairValueInputsLevel3Member cats:WarrantsMember 2017-01-01 2017-03-31 0001136174 cats:DerivativeLiabilityMember 2017-01-01 2017-03-31 0001136174 cats:WarrantLiabilityMember 2017-01-01 2017-03-31 0001136174 cats:WarrantLiabilityMember us-gaap:MaximumMember 2017-01-01 2017-03-31 0001136174 cats:WarrantLiabilityMember us-gaap:MinimumMember 2017-01-01 2017-03-31 0001136174 cats:TwentySeventeenStockIncentivePlanMember 2017-01-01 2017-03-31 0001136174 cats:TwentySeventeenStockIncentivePlanMember us-gaap:MaximumMember 2017-01-01 2017-03-31 0001136174 cats:TwentySeventeenStockIncentivePlanMember us-gaap:MinimumMember 2017-01-01 2017-03-31 0001136174 cats:TwentySeventeenStockIncentivePlanMember cats:EmployeesAndDirectorsMember 2017-01-01 2017-03-31 0001136174 cats:TwentySeventeenStockIncentivePlanMember cats:NonemployeesMember 2017-01-01 2017-03-31 0001136174 cats:FurnitureAndEquipmentMember us-gaap:MaximumMember 2017-01-01 2017-03-31 0001136174 cats:FurnitureAndEquipmentMember us-gaap:MinimumMember 2017-01-01 2017-03-31 0001136174 us-gaap:LeaseholdImprovementsMember us-gaap:MaximumMember 2017-01-01 2017-03-31 0001136174 us-gaap:LeaseholdImprovementsMember us-gaap:MinimumMember 2017-01-01 2017-03-31 0001136174 cats:AcuitasMember cats:January2017ConvertibleDebentureMember 2017-01-01 2017-03-31 0001136174 cats:AcuitasMember cats:January2017ConvertibleDebentureMember 2017-01-01 2017-03-31 0001136174 cats:ShamusMember cats:ConversionOfDecember2016ConvertibleDebenturesIntoCommonStockMember 2017-01-01 2017-03-31 0001136174 cats:EmployeesAndDirectorsMember 2017-01-01 2017-03-31 0001136174 us-gaap:SubsequentEventMember 2017-04-01 2017-04-30 0001136174 cats:JosephGunnerCoLLCMember us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2017-04-25 2017-04-25 0001136174 cats:JosephGunnerCoLLCMember us-gaap:SubsequentEventMember cats:PublicOfferingMember 2017-04-25 2017-04-25 0001136174 cats:ReverseStockSplitMember us-gaap:SubsequentEventMember 2017-04-25 2017-04-25 0001136174 cats:July2015ConvertibleDebentureMember cats:AcuitasMember 2015-07-31 0001136174 cats:July2015ConvertibleDebentureMember cats:AcuitasMember 2015-10-31 0001136174 2015-12-31 0001136174 2016-03-31 0001136174 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2016-06-30 0001136174 us-gaap:FairValueInputsLevel3Member cats:WarrantsMember 2016-06-30 0001136174 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2016-09-30 0001136174 us-gaap:FairValueInputsLevel3Member cats:WarrantsMember 2016-09-30 0001136174 2016-12-31 0001136174 cats:ShamusWarrantsMember cats:ShamusMember 2016-12-31 0001136174 cats:December2016WarrantsMember cats:AcuitasMember 2016-12-31 0001136174 cats:ShamusWarrantsMember cats:ShamusMember 2016-12-31 0001136174 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2016-12-31 0001136174 us-gaap:FairValueInputsLevel3Member cats:WarrantsMember 2016-12-31 0001136174 cats:EmployeesAndDirectorsMember 2016-12-31 0001136174 cats:ShamusWarrantsMember cats:ShamusMember 2017-01-31 0001136174 cats:December2016WarrantsMember cats:AcuitasMember 2017-01-31 0001136174 cats:December2016WarrantsMember cats:AcuitasMember 2017-01-31 0001136174 cats:January2017WarrantsMember cats:AcuitasMember 2017-01-31 0001136174 cats:ShamusWarrantsMember cats:ShamusMember 2017-01-31 0001136174 cats:AcuitasMember cats:January2017ConvertibleDebentureMember 2017-01-31 0001136174 2017-03-31 0001136174 cats:AmendedWarrantsMember 2017-03-31 0001136174 cats:WarrantsNotSubjectToAmendmentMember 2017-03-31 0001136174 cats:ConvertibleDebenturesMember 2017-03-31 0001136174 us-gaap:FairValueInputsLevel1Member 2017-03-31 0001136174 us-gaap:FairValueInputsLevel2Member 2017-03-31 0001136174 us-gaap:FairValueInputsLevel3Member 2017-03-31 0001136174 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2017-03-31 0001136174 us-gaap:FairValueInputsLevel3Member cats:WarrantsMember 2017-03-31 0001136174 cats:DeferredSalariesMember cats:ChairmanAndChiefExecutiveOfficerMember 2017-03-31 0001136174 cats:TwentySeventeenStockIncentivePlanMember 2017-03-31 0001136174 cats:ChairmanAndChiefExecutiveOfficerMember 2017-03-31 0001136174 cats:EmployeesAndDirectorsMember 2017-03-31 0001136174 cats:JosephGunnerCoLLCMember us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2017-04-25 0001136174 cats:JosephGunnerCoLLCMember us-gaap:SubsequentEventMember cats:PublicOfferingMember 2017-04-25 0001136174 2017-05-12

EX-101.SCH 7 cats-20170331.xsd EXHIBIT 101.SCH 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Disclosure - Note 1 - Basis of Consolidation, Presentation and Going Concern link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 4 - Short-term Debt link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 5 - Restatement of Financial Statements link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 6 - Subsequent Event link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 1 - Basis of Consolidation, Presentation and Going Concern (Details Textual) link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Employee and Director Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Fair Value Measurements Using Significant Level III Inputs (Details) link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Fair Value Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 4 - Short-term Debt (Details Textual) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 5 - Restatement of Financial Statements (Details Textual) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 6 - Subsequent Event (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 8 cats-20170331_cal.xml EXHIBIT 101.CAL EX-101.DEF 9 cats-20170331_def.xml EXHIBIT 101.DEF EX-101.LAB 10 cats-20170331_lab.xml EXHIBIT 101.LAB Document And Entity Information Conversion Of December 2016 Convertible Debentures Into Common Stock [Member] Refers to the information regarding the conversion of December 2016 convertible debentures into common stock. Note To Financial Statement Details Textual statementsignificantaccountingpoliciespolicies statementnote2summaryofsignificantaccountingpoliciestables statementnote2summaryofsignificantaccountingpoliciesemployeeanddirectorstockoptionactivitydetails statementnote2summaryofsignificantaccountingpoliciesfairvalueassetsandliabilitiesmeasuredonrecurringbasisdetails statementnote2summaryofsignificantaccountingpoliciesfairvaluemeasurementsusingsignificantleveliiiinputsdetails statementnote2summaryofsignificantaccountingpoliciesfairvalueassumptionsdetails Operating expenses Notes To Financial Statements Notes To Financial Statements [Abstract] Derivatives, Policy [Policy Text Block] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 3 [Member] Investing activities: Fair Value Hierarchy [Domain] Common Stock Issued for Investor Relation Services [Member] Represents stock issued in lieu of cash for investor relation services. Fair Value, Hierarchy [Axis] us-gaap_ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock Interim Period, Costs Not Allocable [Domain] Nature of Expense [Axis] Equity Component [Domain] us-gaap_CashUninsuredAmount Cash, Uninsured Amount Equity Components [Axis] us-gaap_IncreaseDecreaseInDeferredRevenue Deferred revenue cats_WarrantTerm Warrant Term Period of time between issuance and maturity of warrants. us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Accounts payable and other accrued liabilities Short term debt, net of discount Preferred stock, shares outstanding (in shares) Common stock, shares outstanding (in shares) New Accounting Pronouncements, Policy [Policy Text Block] Derivative Financial Instruments, Liabilities [Member] Related Party Transaction [Domain] Related Party Transaction [Axis] us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Basic and diluted weighted number of shares outstanding (in shares) us-gaap_DerivativeGainLossOnDerivativeNet Derivative, Gain (Loss) on Derivative, Net Basic and diluted net loss from operations per share: (in dollars per share) Subsequent Event [Member] Related Party [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Axis] Related Party [Domain] us-gaap_RepaymentsOfLongTermCapitalLeaseObligations Capital lease obligations Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period us-gaap_CashEquivalentsAtCarryingValue Cash Equivalents, at Carrying Value Subsequent Events [Text Block] us-gaap_DebtConversionConvertedInstrumentSharesIssued1 Debt Conversion, Converted Instrument, Shares Issued Scenario, Unspecified [Domain] us-gaap_DebtConversionOriginalDebtAmount1 Debt Conversion, Original Debt, Amount Scenario [Axis] Debt Conversion, Name [Domain] Debt Conversion Description [Axis] Nonmonetary Transaction Type [Domain] Deferred rent Debt Disclosure [Text Block] Nonmonetary Transaction Type [Axis] Expected volatility Healthcare services revenues Warrants [Member] Represents warrants. us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage Cash and Cash Equivalents, Policy [Policy Text Block] Customer Concentration Risk [Member] Maximum [Member] Range [Domain] Minimum [Member] Customer [Axis] Concentration Risk Type [Domain] us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio Significant Accounting Policies [Text Block] Range [Axis] Customer [Domain] Accounting Policies [Abstract] Statement of Financial Position [Abstract] Concentration Risk Type [Axis] Relationship to Entity [Domain] Furniture and Equipment [Member] Represents furniture and equipment. Title of Individual [Axis] us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaids and other current assets us-gaap_LiabilitiesFairValueDisclosure Total liabilities us-gaap_SharesIssuedPricePerShare Shares Issued, Price Per Share Sales Revenue, Net [Member] Statement of Cash Flows [Abstract] Accounts Receivable [Member] Fair Value by Liability Class [Domain] Liability Class [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Axis] Proceeds from bridge loan Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Supplemental disclosure of non-cash activity Change in fair value us-gaap_IncreaseDecreaseInAccountsReceivable Receivables us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Cancelled (in shares) Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross cats_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByEachWarrantOrRight Class of Warrant or Right, Number of Additional Securities Called by Each Warrant or Right Number of additional securities into which each warrant or right may be converted after certain amendments. For example, but not limited to, each warrant may be converted into two shares. Amended Warrants [Member] Information on the warrants covered under certain agreements. us-gaap_StockIssuedDuringPeriodSharesIssuedForServices Stock Issued During Period, Shares, Issued for Services cats_ClassOfWarrantOrRightValueOfSecuritiesCalled Class of Warrant or Right, Value of Securities Called The value of securities that will be called by certain warrants or rights issued. us-gaap_ProceedsFromIssuanceOfDebt Proceeds from Issuance of Debt cats_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentOfSharePrice Class of Warrant or Right, Exercise Price of Warrants or Rights, Percent of Share Price Exercise price per share or per unit of warrants or rights outstanding expressed as a percentage of the initial public offering price. Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Warrants not Subject to Amendment [Member] Information regarding the warrants not subject to certain amendments. cats_SharesIssuedPricePerShareNet Shares Issued, Price Per Share, Net The per share value of shares issued, net of underwriter costs, discounts, and commissions. cats_DebtInstrumentExtendedMaturity Debt Instrument, Extended Maturity Amount of debt instrument of which the maturity is extended. Convertible Debentures [Member] Related to convertible debt instruments. us-gaap_StockIssuedDuringPeriodSharesNewIssues Stock Issued During Period, Shares, New Issues Joseph Gunner & Co. LLC [Member] Related to the underwriter of the public offering, Joseph Gunner & Co. LLC. cats_AdditionalSharesAvailableForPurchase Additional Shares Available for Purchase The maximum number of additional shares available for purchase under certain underwriting agreements. us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Loss from operations before provision for income taxes Public Offering [Member] Related to the public offering. us-gaap_LiabilitiesAndStockholdersEquity Total Liabilities and Stockholders' Deficit Provision for income taxes Income Tax Expense (Benefit) Accumulated deficit Derivative Liability us-gaap_PolicyTextBlockAbstract Accounting Policies us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings Change in fair value of derivative liability us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Balance Balance Deferred rent and other long-term liabilities Statement [Table] Issuance (exercise) of warrants, net Income Statement [Abstract] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Financing activities: Capital leases Class of Stock [Axis] Award Type [Axis] Equity Award [Domain] Fair Value of Financial Instruments, Policy [Policy Text Block] Prepaids and other current assets Expected dividend us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Risk-free interest rate Long-term liabilities Weighted average expected lives in years (Year) us-gaap_LiabilitiesCurrent Total current liabilities Changes in current assets and liabilities: Revenues: Short term debt, related party, net of discount $0 and $216, respectively Due to Related Parties, Current Earnings Per Share, Policy [Policy Text Block] Shamus Warrants [Member] Information pertaining to the Shamus Warrants. Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block] us-gaap_OperatingExpenses Total operating expenses Income Tax, Policy [Policy Text Block] December 2016 Warrants [Member] Information pertaining to the December 2016 warrants. cats_ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRightsUponConversion Class of Warrant or Right, Percent of Securities Called by Warrants or Rights Upon Conversion Represents the percentage of securities in which the class of warrant or right me be converted upon conversion, including, but not limited to a debt instrument. Share-based Compensation, Stock Options, Activity [Table Text Block] General and administrative Accounting Changes and Error Corrections [Text Block] Derivative liability us-gaap_OperatingIncomeLoss Loss from operations Deferred revenue Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Amendment Flag Common stock, $0.0001 par value; 500,000,000 shares authorized; 9,443,749 and 9,214,743 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively Fair value adjustment on warrant liability Change in fair value of warrant liability Common stock, shares authorized (in shares) Loss on conversion of note Loss on conversion of note The amount of gain (loss) recognized on the conversion of debt instruments. Common stock, shares issued (in shares) Shares issued for services Deposits and other assets Common stock, par value (in dollars per share) Share-based compensation expense Share-based Compensation cats_NetProceedsFromIssuanceOrSaleOfEquity Net Proceeds from Issuance or Sale of Equity The net cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. Short-term Debt, Type [Domain] Current Fiscal Year End Date Reverse Stock Split [Member] The conversion of a reverse stock split where there is a reduction in the shares outstanding Issuance costs included in interest expense Short-term Debt, Type [Axis] Cost of Sales, Policy [Policy Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Document Fiscal Period Focus Document Fiscal Year Focus Document Period End Date Cost of healthcare services Preferred stock, $0.0001 par value; 50,000,000 shares authorized; no shares issued and outstanding Preferred stock, shares issued (in shares) Document Type us-gaap_DepreciationDepletionAndAmortization Depreciation and amortization Preferred stock, shares authorized (in shares) Accounts payable Document Information [Line Items] Document Information [Table] Preferred stock, par value (in dollars per share) Long-term assets Accrued compensation and benefits us-gaap_AssetsCurrent Total current assets Entity Filer Category EX-101.PRE 11 cats-20170331_pre.xml EXHIBIT 101.PRE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2017	May 12, 2017
Document Information [Line Items]
Entity Registrant Name	CATASYS, INC.
Entity Central Index Key	0001136174
Trading Symbol	cats
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		15,874,678
Document Type	10-Q
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
Amendment Flag	false

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 291	$ 851
Receivables, net of allowance for doubtful accounts of $149 and $0, respectively	1,263	1,052
Prepaids and other current assets	596	420
Total current assets	2,150	2,323
Long-term assets
Property and equipment, net of accumulated depreciation of $1,660 and $1,620, respectively	419	410
Deposits and other assets	371	371
Total Assets	2,940	3,104
Current liabilities
Accounts payable	1,221	870
Accrued compensation and benefits	2,020	2,089
Deferred revenue	1,943	1,525
Other accrued liabilities	582	575
Short term debt, related party, net of discount $0 and $216, respectively	10,046	9,796
Derivative liability	18,718	8,122
Total current liabilities	34,530	22,977
Long-term liabilities
Deferred rent and other long-term liabilities	95	117
Capital leases	22	31
Warrant Liabilities, Noncurrent	12,893	5,307
Total Liabilities	47,540	28,432
Stockholders' deficit
Preferred stock, $0.0001 par value; 50,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.0001 par value; 500,000,000 shares authorized; 9,443,749 and 9,214,743 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively	6	6
Additional paid-in-capital	256,881	254,385
Accumulated deficit	(301,487)	(279,719)
Total Stockholders' Deficit	(44,600)	(25,328)
Total Liabilities and Stockholders' Deficit	$ 2,940	$ 3,104

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Receivables, allowance for doubtful accounts	$ 149	$ 0
Property and equipment, accumulated dereciation	1,660	1,620
Short term debt, net of discount	$ 0	$ 216
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	50,000,000	50,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, shares issued (in shares)	9,443,749	9,214,743
Common stock, shares outstanding (in shares)	9,443,749	9,214,743

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenues:
Healthcare services revenues	$ 1,822,000	$ 728,000
Operating expenses
Cost of healthcare services	1,365,000	966,000
General and administrative	2,629,000	2,187,000
Depreciation and amortization	39,000	32,000
Total operating expenses	4,033,000	3,185,000
Loss from operations	(2,211,000)	(2,457,000)
Other income	(14,000)	(65,000)
Interest expense	(2,867,000)	(333,000)
Loss on conversion of note	(926,000)
Change in fair value of warrant liability	(5,181,000)	(228,000)
Change in fair value of derivative liability	(10,596,000)	(1,337,000)
Loss from operations before provision for income taxes	(21,767,000)	(4,290,000)
Provision for income taxes	0	2,000
Net Loss	$ (21,768,000)	$ (4,292,000)
Basic and diluted net loss from operations per share: (in dollars per share)	$ (2.35)	$ (0.47)
Basic and diluted weighted number of shares outstanding (in shares)	9,246	9,168

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Operating activities:
Net loss	$ (21,768)	$ (4,292)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	39	32
Issuance costs included in interest expense	2,622	216
Provision for doubtful accounts	149	7
Deferred rent	(20)	(23)
Share-based compensation expense	127	174
Fair value adjustment on derivative liability	10,596	1,337
Fair value adjustment on warrant liability	5,181	228
Shares issued for services	117
Loss on conversion of note	926
Changes in current assets and liabilities:
Receivables	(360)	(27)
Prepaids and other current assets	(176)	141
Deferred revenue	418	593
Accounts payable and other accrued liabilities	534	96
Net cash used in operating activities	(1,615)	(1,518)
Investing activities:
Purchases of property and equipment	(49)	(10)
Deposits and other assets		16
Net cash provided by/(used in) investing activities	(49)	6
Financing activities:
Proceeds from bridge loan	1,115	900
Capital lease obligations	(11)	(42)
Net cash provided by financing activities	1,104	858
Net decrease in cash and cash equivalents	(560)	(654)
Cash and cash equivalents at beginning of period	851	916
Cash and cash equivalents at end of period	291	262
Supplemental disclosure of cash paid
Income taxes	39	26
Supplemental disclosure of non-cash activity
Common stock issued for investor relations services	$ 117

XML 17 R6.htm IDEA: XBRL DOCUMENT

Note 1 - Basis of Consolidation, Presentation and Going Concern	3 Months Ended
	Mar. 31, 2017
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Basis of Consolidation, Presentation and Going Concern The accompanying unaudited condensed consolidated financial statements for Catasys, Inc. and its subsidiaries have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and instructions to Form 10 -Q and, therefore, do not include all disclosures necessary for a complete presentation of financial position, results of operations, and cash flows in conformity with U.S. GAAP. In our opinion, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of the results that may be expected for the entire fiscal year. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto included in our most recent Annual Report on Form 10 -K for the year-ended December 31, 2016, from which the balance sheets, as of December 31, 2016, have been derived. Our financial statements have been prepared on the basis that we will continue as a going concern. At March 31, 2017, cash and cash equivalents was $291,000 and we had a working capital deficit of approximately $32.4 million. We have incurred significant operating losses and negative cash flows from operations since our inception. During the three months ended March 31, 2017, our cash used in operating activities was $1.6 million. We anticipate that we could continue to incur negative cash flows and net losses for the next twelve months. The financial statements do not include any adjustments relating to the recoverability of the carrying amount of the recorded assets or the amount of liabilities that might result from the outcome of this uncertainty. As of March 31, 2017, these conditions raised substantial doubt as to our ability to continue as a going concern. In April 2017, we closed on a public offering for aggregate gross proceeds of $16.5 million prior to deducting underwriter discounts, commission and other estimated offering expenses. We expect our current cash resources to cover expenses through at least the next twelve month.

XML 18 R7.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2017

Notes to Financial Statements

Significant Accounting Policies [Text Block]

Note

Summary of Significant Accounting Policies

Revenue Recognition

Our Catasys contracts are generally designed to provide cash fees to us on a monthly basis or an upfront case rate based on enrolled members. To the extent our contracts

may

include a minimum performance guarantee; we reserve a portion of the fees that

may

be at risk until the performance measurement period is completed. To the extent we receive case rates or other fees in advance that are not subject to the performance guarantees, we recognize the case rate ratably over the

twelve

months of our program. We recognize any fees from sharing in the savings generated from enrolled members when we receive payment.

Cost of Services

third

party administrators for processing these claims. Salaries and fees charged by our

third

party administrators for processing claims are expensed when incurred and healthcare provider claims payments are recognized in the period in which an eligible member receives services. We contract with doctors and licensed behavioral healthcare professionals, on a fee-for-service basis. We determine that a member has received services when we receive a claim or in the absence of a claim, by utilizing member data recorded in the eOn

Trak

database within the contracted timeframe, with all required billing elements correctly completed by the service provider.

Cash Equivalents and Concentration of Credit Risk

We consider all highly liquid investments with an original maturity of

three

months or less to be cash equivalents. Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Cash is deposited with what we believe are highly credited, quality financial institutions. The deposited cash

may

exceed Federal Deposit Insurance Corporation (“FDIC”) insured limits. As of

March

31,

2017,

cash and cash equivalents exceeding federally insured limits totaled

$115,038.

For the

three

months ended

March

31,

2017,

three

customers accounted for approximately

94%

of revenues and

two

customers accounted for approximately

79%

of accounts receivable.

Basic and Diluted

Income (Loss) per Share

Common equivalent shares, consisting of

1,928,431

and

620,119

common shares for the

three

months ended

March

31,

2017

and

2016,

respectively, issuable upon the exercise of stock options and warrants have been excluded from the diluted earnings per share calculation as their effect is anti-dilutive.

Share-Based Compensation

Our

2017

Stock Incentive Plan (the

“2017

Plan”), provides for the issuance of up to

2,333,334

shares of our common stock. Incentive stock options (ISOs) under Section

422A

of the Internal Revenue Code and non-qualified options (NSOs) are authorized under the Plan. We have granted stock options to executive officers, employees, members of our board of directors, and certain outside consultants. The terms and conditions upon which options become exercisable vary among grants, but option rights expire no later than

ten

years from the date of grant and employee and board of director awards generally vest over

three

five

years. As of

March

31,

2017,

we had

243,853

vested and unvested shares outstanding and

50,774

shares available for future awards under the Plan.

Total share-based compensation expense on a consolidated basis was

$127,000

and

$174,000

for the

three

months ended

March

31,

2017

and

2016,

respectively.

Stock Options – Employees and Directors

Share-based compensation expense recognized for employees and directors for the

three

months ended

March

31,

2017

and

2016

was

$127,000

and

$174,000,

respectively.

three

months ended

March

31,

2017

and

2016,

is based on awards ultimately expected to vest, reduced for estimated forfeitures. Accounting rules for stock options require forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

There were

options granted to employees and directors during the

three

months ended

March

31,

2017

and

2016,

respectively, under the

2017

Plan. Employee and director stock option activity for the

three

months ended

March

31,

2017

are as follows:

			Weighted Avg.
	Shares		Exercise Price
Balance December 31, 2016		244,000	$	39.06

Granted		-	$	-
Cancelled		-	$	-

Balance March 31, 2017		244,000	$	38.90

three

months ended

March

31,

2017

and

2016,

reflects the application of the simplified method prescribed in SEC Staff Accounting Bulletin (“SAB”) No.

107

(as amended by SAB

110),

which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches.

As of

March

31,

2017,

there was

$191,000

of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plan. That cost is expected to be recognized over a weighted-average period of approximately

1.52

years.

Stock Options and Warrants – Non-employees

There were

options issued to non-employees for the

three

months ended

March

31,

2017

and

2016,

respectively. There was

share-based compensation expense relating to stock options and warrants recognized for the non-employees for the

three

months ended

March

31,

2017

and

2016,

respectively.

Common Stock

There were

14,492

and

shares of common stock issued in exchange for investor relations services during the

three

months ended

March

31,

2017

and

2016,

respectively. Generally, the costs associated with shares issued for services are amortized to the related expense on a straight-line basis over the related service periods.

There were

214,514

shares of common stock issued to Shamus, LLC (“Shamus”),

a Company owned by David E. Smith, a member of our board of directors for the conversion of their

December

2016

Convertible Debentures.

Income Taxes

We have recorded a full valuation allowance against our otherwise recognizable deferred tax assets as of

March

31,

2017.

As such, we have

not

recorded a provision for income tax for the period ended

March

31,

2017.

We utilize the liability method of accounting for income taxes as set forth in ASC

740,

Income Taxes. Under the liability method, deferred taxes are determined based on the temporary differences between the financial statement and tax basis of assets and liabilities using tax rates expected to be in effect during the years in which the basis differences reverse. A valuation allowance is recorded when it is more likely than not that some of the deferred tax assets will not be realized.

50%

likelihood that a tax benefit will be sustained, we have recorded the largest amount of tax benefit that

may

potentially be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is less than

50%

likelihood that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements. Based on management's assessment of the facts, circumstances and information available, management has determined that all of the tax benefits for the period ended

March

31,

2017

should be realized.

Fair Value Measurements

(1)

market participant assumptions developed based on market data obtained from independent sources (observable inputs) and

(2)

an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of

three

broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level I) and the lowest priority to unobservable inputs (Level III). The

three

levels of the fair value hierarchy are described below:

Level Input:		Input Definition:
Level I		Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
Level II		Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.
Level III		Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.

The following table summarizes fair value measurements by level at

March

31,

2017

for assets and liabilities measured at fair value:

	Balance at March 31, 2017


(Amounts in thousands)	Level I		Level II		Level III		Total
Certificates of deposit		106		-		-		106
Total assets		106		-		-		106

Warrant liabilities		-		-		12,893		12,893
Derivative Liability						18,718		18,718
Total liabilities		-		-		31,611		31,611

Financial instruments classified as Level III in the fair value hierarchy as of

March

31,

2017,

represent our liabilities measured at market value on a recurring basis which include warrant liabilities and derivative liabilities resulting from recent debt and equity financings. In accordance with current accounting rules, the warrant liabilities and derivative liabilities are being marked-to-market each quarter-end until they are completely settled or expire. The warrants and derivative liabilities are valued using the Black-Scholes option-pricing model, using both observable and unobservable inputs and assumptions consistent with those used in our estimate of fair value of employee stock options. See

Warrant Liabilities

below.

The following table summarizes our fair value measurements using significant Level III inputs, and changes therein, for the

three

months ended

March

31,

2017:

	Level III			Level III
	Warrant			Derivative
(Dollars in thousands)	Liabilities		(Dollars in thousands)	Liabilities
Balance as of December 31, 2016	$	5,307	Balance as of December 31, 2016	$	8,122
Issuance of warrants		2,405	Issuance of warrants		-
Change in fair value		5,181	Change in fair value		10,596
Balance as of March 31, 2017	$	12,893	Balance as of March 31, 2017	$	18,718

Issuance (exercise) of warrants, net		-	Issuance (exercise) of warrants, net		-
Change in fair value		-	Change in fair value		-
Balance as of June 30, 2016	$	12,893	Balance as of June 30, 2016	$	18,718

Issuance (exercise) of warrants, net		-	Issuance (exercise) of warrants, net		-
Expiration of warrants		-	Expiration of warrants		-
Change in fair value		-	Change in fair value		-
Balance as of September 30, 2016	$	12,893	Balance as of September 30, 2016	$	18,718

Property and Equipment

two

seven

years for furniture and equipment. Leasehold improvements are amortized over the lesser of the estimated useful lives of the assets or the related lease term, which is typically

five

seven

years.

Warrant Liabilities

January

2017,

we entered into a Subscription Agreement (the “Subscription Agreement”) with Acuitas Group Holdings, LLC (“Acuitas”),

one

hundred percent

(100%)

of which is owned by Terren S. Peizer, Chairman and Chief Executive Officer of the Company, pursuant to which we will receive aggregate gross proceeds of

$1,300,000

(the “Loan Amount”) in consideration of the issuance of (i) an

Series B Convertible Debenture due

March

31,

2017

(the

“January

2017

Convertible Debenture”) and (ii)

five

-year warrants to purchase shares of the Company’s common stock in an amount equal to

one

hundred percent

(100%)

of the initial number of shares of common stock issuable upon the conversion of the

January

2017

Convertible Debenture, at an exercise price of

$5.10

per share (the

“January

2017

Warrants”). The Loan Amount is payable in tranches through

March

31,

2017,

and as of

March

31,

2017

we have received

$1,115,000.

In addition, any warrants issued in conjunction with the

December

2016

Convertible Debenture currently outstanding with Acuitas have been increased by an additional

25%

warrant coverage, exercisable for an aggregate of

137,883

shares of the Company’s common stock. Acuitas agreed to extend the maturity date of the

January

2017

Convertible Debenture to

April

30,

2017

or until we complete a public offering, whichever comes

first.

The

January

2017

Warrants include, among other things, price protection provisions pursuant to which, subject to certain exempt issuances, the then exercise price of the

January

2017

Warrants will be adjusted if the Company issues shares of common stock at a price that is less than the then exercise price of the

January

2017

Warrants. Such price protection provisions will remain in effect until the earliest of (i) the termination date of the

January

2017

Warrants, (ii) such time as the

January

2017

Warrants are exercised or (iii) contemporaneously with the listing of the Company’s shares of common stock on a registered national securities exchange.

In connection with the Subscription Agreement described above, the number of Shamus warrants issued as part of the

December

2016

Convertible Debenture were increased from

75%

100%

warrant coverage, exercisable for an aggregate of

58,824

shares of the Company’s common stock.

The warrant liabilities were calculated using the Black-Scholes model based upon the following assumptions:

	March 31, 201 7
Expected volatility		93.56%
Risk-free interest rate	1.27	-	1.93%
Weighted average expected lives in years	2	-	5
Expected dividend		0%

We have issued warrants to purchase common stock in

February

2012,

April

2015,

July

2015,

August

2016,

December

2016,

January

2017,

February

2017

and

March

2017.

The warrants are being accounted for as liabilities in accordance with FASB accounting rules, due to anti-dilution provisions in some warrants that protect the holders from declines in our stock price, which is considered outside our control. The warrants are marked-to-market each reporting period, using the Black-Scholes pricing model, until they are completely settled or expire.

For the

three

months ended

March

31,

2017

and

2016,

we recognized a loss of

$5.2

million and

$228,000,

respectively, related to the revaluation of our warrant liabilities.

Derivative Liability

July

2015,

we entered into a

$3.55

million

12%

Original Issue Discount Convertible Debenture due

January

18,

2016

with Acuitas (the

“July

2015

Convertible Debenture”). The conversion price of the

July

2015

Convertible Debenture is

$11.40

per share, subject to adjustments, including for issuances of common stock and common stock equivalents below the then current conversion or exercise price, as the case

may

be. In

October

2015,

we entered into an amendment of the

July

2015

Convertible Debenture which extended the maturity date of the

July

2015

Convertible Debenture from

January

18,

2016

January

18,

2017.

In addition, the conversion price of the

July

2015

Convertible Debenture was subsequently adjusted to

$1.80

per share. The

July

2015

Convertible Debenture is unsecured, bears interest at a rate of

12%

per annum payable in cash or shares of common stock, subject to certain conditions, at our option, and is subject to mandatory prepayment upon the consummation of certain future financings. Acuitas agreed to extend the maturity date of the

July

2015

Convertible Debenture to

April

30,

2017

or until we complete a public offering, whichever comes

first.

The derivative liability associated with the

July

2015

Convertible Debenture was calculated using the Black-Scholes model based upon the following assumptions:

	March 31, 201 7
Expected volatility		93.56	%
Risk-free interest rate		0.74	%
Weighted average expected lives in years		0.08
Expected dividend		0	%

For the

three

months ended

March

31,

2017

and

2016,

we recognized a loss of

$10.6

million and

$1.3

million related to the revaluation of our derivative liability, respectively.

Recently Issued or Newly Adopted Accounting Standards

April

2016,

the FASB issued Accounting Standards Update (“ASU”)

2016

10,

Revenue from Contracts with Customers (Topic

606)

, which amends certain aspects of the Board’s new revenue standard, ASU

2014

09,

Revenue from Contracts with Customers. The standard should be adopted concurrently with adoption of ASU

2014

09,

which is effective for annual and interim periods beginning after

December

15,

2017.

Early adoption is permitted. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

March

2016,

the FASB issued ASU

2016

09,

Compensation — Stock Compensation (Topic

718):

Improvements to Employee Share-Based Payment Accounting

(“ASU

2016

09”),

which outlines new provisions intended to simplify various aspects related to accounting for share-based payments and their presentation in the financial statements. The standard is effective for the Company for fiscal years beginning after

December

15,

2016,

and interim periods within those annual periods. Early adoption is permitted. The adoption of ASU

2016

did not have a material effect on our consolidated financial positon or results of operations.

February

2015,

the FASB issued ASU,

Consolidation (Topic

810):

Amendments to the Consolidation Analysis

(“ASU

2015

02”).

ASU

2015

modifies existing consolidation guidance for reporting organizations that are required to evaluate whether they should consolidate certain legal entities. ASU

2015

is effective for fiscal years and interim periods within those years beginning after

December

15,

2015,

and requires either a retrospective or a modified retrospective approach to adoptions. The adoption of ASU

2015

did not have a material effect on our consolidated financial position or results of operations.

August

2014,

the FASB issued FASB ASU

2014

15,

Presentation of Financial Statements—Going Concern (Subtopic

205

40):

Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern

(“ASU

2014

15”)

ASU

2014

changes the disclosure of uncertainties about an entity’s ability to continue as a going concern. Under U.S. GAAP, continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Even if an entity’s liquidation is not imminent, there

may

be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. Because there is no guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related note disclosures, there is diversity in practice whether, when, and how an entity discloses the relevant conditions and events in its financial statements. As a result, these changes require an entity’s management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within

one

year after the date that financial statements are issued. Substantial doubt is defined as an indication that it is probable that an entity will be unable to meet its obligations as they become due within

one

year after the date that financial statements are issued. If management has concluded that substantial doubt exists, then the following disclosures should be made in the financial statements: (i) principal conditions or events that raised the substantial doubt, (ii) management’s evaluation of the significance of those conditions or events in relation to the entity’s ability to meet its obligations, (iii) management’s plans that alleviated the initial substantial doubt or, if substantial doubt was not alleviated, management’s plans that are intended to at least mitigate the conditions or events that raise substantial doubt, and (iv) if the latter in (iii) is disclosed, an explicit statement that there is substantial doubt about the entity’s ability to continue as a going concern. ASU

2014

is effective for periods beginning after

December

15,

2016.

The adoption of ASU

2014

did not have a material effect on our consolidated position or results of operations.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Note 3 - Related Party Disclosure	3 Months Ended
Note 3 - Related Party Disclosure	Mar. 31, 2017
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 3. Related Party Disclosure In January 2017, we entered into the Subscription Agreement with Acuitas pursuant to which we will receive aggregate gross proceeds of $1,300,000 (the “Loan Amount”) in consideration of the issuance of the January 2017 Convertible Debenture and the January 2017 Warrants The Loan Amount is payable in tranches through March 31, 2017, and as of March 31, 2017 we have received $1,115,000. In addition, any warrants issued in conjunction with the December 2016 Convertible Debenture currently outstanding with Acuitas have been increased by an additional 25% warrant coverage, exercisable for an aggregate of 137,883 shares of the Company’s common stock. In addition, we have accounts payable outstanding with Mr. Peizer for travel and expenses of $204,000 as of March 31, 2017 and deferred salary of $1.1 million as of March 31, 2017. In January 2017, in connection with the Subscription Agreement described above, the number of Shamus warrants issued as part of the December 2016 Convertible Debenture were increased from 75% to 100% warrant coverage, exercisable for an aggregate of 14,706 shares of the Company’s common stock. In March 2017, Shamus converted $1.3 million of their December 2016 Convertible Debentures and accrued interest for 214,514 shares of our common stock.

XML 20 R9.htm IDEA: XBRL DOCUMENT

Note 4 - Short-term Debt	3 Months Ended
Note 4 - Short-term Debt	Mar. 31, 2017
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 4. Short-term Debt In January 2017, we entered into a Subscription Agreement (the “Subscription Agreement”) with Acuitas,, pursuant to which we will receive aggregate gross proceeds of $1,300,000 (the “Loan Amount”) in consideration of the issuance of (i) an 8% Series B Convertible Debenture due March 31, 2017 (the “January 2017 Convertible Debenture”) and (ii) five -year warrants to purchase shares of the Company’s common stock in an amount equal to one hundred percent (100%) of the initial number of shares of common stock issuable upon the conversion of the January 2017 Convertible Debenture, at an exercise price of $5.10 per share (the “January 2017 Warrants”). The Loan Amount is payable in tranches through March 31, 2017, and as of March 31, 2017 we have received $1,115,000. In addition, any warrants issued in conjunction with the December 2016 Convertible Debenture currently outstanding with Acuitas have been increased by an additional 25% warrant coverage, exercisable for an aggregate of 137,883 shares of the Company’s common stock. Acuitas agreed to extend the maturity date of the January 2017 Convertible Debenture to April 30, 2017 or until we complete a public offering, whichever comes first.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Note 5 - Restatement of Financial Statements	3 Months Ended
Note 5 - Restatement of Financial Statements	Mar. 31, 2017
Notes to Financial Statements
Accounting Changes and Error Corrections [Text Block]	Note 5. Restatement of Financial Statements The financial statements have been retroactively restated to reflect the 1 -for- 6 reverse-stock split that occurred on April 25, 2017.

XML 22 R11.htm IDEA: XBRL DOCUMENT

Note 6 - Subsequent Event	3 Months Ended
Note 6 - Subsequent Event	Mar. 31, 2017
Notes to Financial Statements
Subsequent Events [Text Block]	Note 6. Subsequent Event Amendments to Outstanding Warrants and Extension of Existing Debentures In March 2017, we entered into amendments with the holders of certain outstanding warrants issued on April 17, 2015 and July 30, 2015 to eliminate certain anti-dilution provisions in such warrants, which caused us to reflect an associated liability of $12.8 million on our balance sheet as of March 31, 2017. Such amendments did not take effect until April 28, 2017. For each warrant share underlying the warrants so amended, the holder received the right to purchase an additional .2 shares of common stock. Two of the holders of such warrants, which owners hold warrants to purchase an aggregate of 11,049 shares of common stock, did not agree to the amendment. The warrant holders agreeing to the amendment include Acuitas and another accredited investor. Additionally, in March 2017, we and the holders of an aggregate of approximately $10 million of our existing convertible debentures agreed to extend the maturity dates of such debentures until April 28, 2017. Reverse Stock Split On April 21, 2017, we filed a certificate of amendment to our Certificate of Incorporation, as amended and in effect, with the Secretary of State of the State of Delaware, implementing a 1 -for- 6 reverse stock split of the Company's common stock, pursuant to which each six shares of issued and outstanding common stock converted into one share of common stock. Proportionate voting rights and other rights of common stock holders will not be affected by the reverse stock split. No fractional shares of common stock were issued as a result of the reverse stock split; stockholders were paid cash in lieu of any such fractional shares. The 1 -for- 6 reverse stock split became effective at 5:00 p.m., Eastern Time, on April 24, 2017, and our common stock began trading on the OTCQB Marketplace on a post-split basis at the open of trading on April 25, 2017. Our post-reverse split common stock has a new CUSIP number: 149049 504. Other terms of the common stock are not affected by the reverse stock split. The common stock will continue to trade under the symbol "CATS." All stock options and warrants to purchase common stock outstanding and our Common Stock reserved for issuance under the Company's equity incentive plans immediately prior to the reverse stock split were appropriately adjusted by dividing the number of affected shares of common stock by six and, as applicable, multiplying the exercise price by six as a result of the reverse stock split. Public Offering On April 25, 2017, we entered into an underwriting agreement with Joseph Gunnar & Co., LLC, as underwriter in connection with a public offering of the Company’s securities. Pursuant to the underwriting agreement, we agreed to issue and sell an aggregate of 3,125,000 shares of Common Stock at a public offering price of $4.80 per share, and the purchase price to the underwriter after discounts and commissions was $4.464 per share. The closing of the offering occurred on April 28, 2017. The Company received $14.8 million in net proceeds in connection with this offering. Pursuant to the underwriting agreement, we issued to the underwriter a warrant for the purchase of an aggregate of 156,250 shares of Common Stock for an aggregate purchase price of $100. The exercise price of the warrant is equal to 125% of the public offering price in the offering, or $6.00 per share of Common Stock. NASDAQ Uplisting In connection with the public offering, our Common Stock began trading on the NASDAQ Capital Market under the symbol “CATS” beginning on April 26, 2017. Exercise of Over-Allotment Option Pursuant to the underwriting with Joseph Gunnar & Co., LLC dated April 25, 2017, we agreed to issue to the underwriters a 45 -day over-allotment option to purchase up to 468,750 additional shares of Common Stock at the public offering price less the applicable underwriter discount. On May 2, 2017, the underwriter acquired an additional 303,750 shares pursuant to such over-allotment option.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

Our Catasys contracts are generally designed to provide cash fees to us on a monthly basis or an upfront case rate based on enrolled members. To the extent our contracts

may

include a minimum performance guarantee; we reserve a portion of the fees that

may

twelve

months of our program. We recognize any fees from sharing in the savings generated from enrolled members when we receive payment.

Cost of Sales, Policy [Policy Text Block]

Cost of Services

third

party administrators for processing these claims. Salaries and fees charged by our

third

Trak

database within the contracted timeframe, with all required billing elements correctly completed by the service provider.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash Equivalents and Concentration of Credit Risk

We consider all highly liquid investments with an original maturity of

three

may

exceed Federal Deposit Insurance Corporation (“FDIC”) insured limits. As of

March

31,

2017,

cash and cash equivalents exceeding federally insured limits totaled

$115,038.

For the

three

months ended

March

31,

2017,

three

customers accounted for approximately

94%

of revenues and

two

customers accounted for approximately

79%

of accounts receivable.

Earnings Per Share, Policy [Policy Text Block]

Basic and Diluted

Income (Loss) per Share

Common equivalent shares, consisting of

1,928,431

and

620,119

common shares for the

three

months ended

March

31,

2017

and

2016,

respectively, issuable upon the exercise of stock options and warrants have been excluded from the diluted earnings per share calculation as their effect is anti-dilutive.

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Share-Based Compensation

Our

2017

Stock Incentive Plan (the

“2017

Plan”), provides for the issuance of up to

2,333,334

shares of our common stock. Incentive stock options (ISOs) under Section

422A

ten

years from the date of grant and employee and board of director awards generally vest over

three

five

years. As of

March

31,

2017,

we had

243,853

vested and unvested shares outstanding and

50,774

shares available for future awards under the Plan.

Total share-based compensation expense on a consolidated basis was

$127,000

and

$174,000

for the

three

months ended

March

31,

2017

and

2016,

respectively.

Stock Options – Employees and Directors

Share-based compensation expense recognized for employees and directors for the

three

months ended

March

31,

2017

and

2016

was

$127,000

and

$174,000,

respectively.

three

months ended

March

31,

2017

and

2016,

There were no options granted to employees and directors during the

three

months ended

March

31,

2017

and

2016,

respectively, under the

2017

Plan. Employee and director stock option activity for the

three

months ended

March

31,

2017

are as follows:

			Weighted Avg.
	Shares		Exercise Price
Balance December 31, 2016		244,000	$	39.06

Granted		-	$	-
Cancelled		-	$	-

Balance March 31, 2017		244,000	$	38.90

three

months ended

March

31,

2017

and

2016,

reflects the application of the simplified method prescribed in SEC Staff Accounting Bulletin (“SAB”) No.

107

(as amended by SAB

110),

which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches.

As of

March

31,

2017,

there was

$191,000

1.52

years.

Stock Options and Warrants – Non-employees

There were no options issued to non-employees for the

three

months ended

March

31,

2017

and

2016,

respectively. There was no share-based compensation expense relating to stock options and warrants recognized for the non-employees for the

three

months ended

March

31,

2017

and

2016,

respectively.

Stockholders' Equity, Policy [Policy Text Block]

Common Stock

There were

14,492

and

shares of common stock issued in exchange for investor relations services during the

three

months ended

March

31,

2017

and

2016,

respectively. Generally, the costs associated with shares issued for services are amortized to the related expense on a straight-line basis over the related service periods.

There were

214,514

shares of common stock issued to Shamus, LLC (“Shamus”),

a Company owned by David E. Smith, a member of our board of directors for the conversion of their

December

2016

Convertible Debentures.

Income Tax, Policy [Policy Text Block]

Income Taxes

We have recorded a full valuation allowance against our otherwise recognizable deferred tax assets as of

March

31,

2017.

As such, we have not recorded a provision for income tax for the period ended

March

31,

2017.

We utilize the liability method of accounting for income taxes as set forth in ASC

740,

50%

likelihood that a tax benefit will be sustained, we have recorded the largest amount of tax benefit that

may

potentially be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is less than

50%

March

31,

2017

should be realized.

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value Measurements

(1)

market participant assumptions developed based on market data obtained from independent sources (observable inputs) and

(2)

an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of

three

levels of the fair value hierarchy are described below:

Level Input:		Input Definition:
Level I		Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
Level II		Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.
Level III		Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.

The following table summarizes fair value measurements by level at

March

31,

2017

for assets and liabilities measured at fair value:

	Balance at March 31, 2017


(Amounts in thousands)	Level I		Level II		Level III		Total
Certificates of deposit		106		-		-		106
Total assets		106		-		-		106

Warrant liabilities		-		-		12,893		12,893
Derivative Liability						18,718		18,718
Total liabilities		-		-		31,611		31,611

Financial instruments classified as Level III in the fair value hierarchy as of

March

31,

2017,

Warrant Liabilities

below.

The following table summarizes our fair value measurements using significant Level III inputs, and changes therein, for the

three

months ended

March

31,

2017:

	Level III			Level III
	Warrant			Derivative
(Dollars in thousands)	Liabilities		(Dollars in thousands)	Liabilities
Balance as of December 31, 2016	$	5,307	Balance as of December 31, 2016	$	8,122
Issuance of warrants		2,405	Issuance of warrants		-
Change in fair value		5,181	Change in fair value		10,596
Balance as of March 31, 2017	$	12,893	Balance as of March 31, 2017	$	18,718

Issuance (exercise) of warrants, net		-	Issuance (exercise) of warrants, net		-
Change in fair value		-	Change in fair value		-
Balance as of June 30, 2016	$	12,893	Balance as of June 30, 2016	$	18,718

Issuance (exercise) of warrants, net		-	Issuance (exercise) of warrants, net		-
Expiration of warrants		-	Expiration of warrants		-
Change in fair value		-	Change in fair value		-
Balance as of September 30, 2016	$	12,893	Balance as of September 30, 2016	$	18,718

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

two

seven

years for furniture and equipment. Leasehold improvements are amortized over the lesser of the estimated useful lives of the assets or the related lease term, which is typically

five

seven

years.

Warrant Liabilities, Policy [Policy Text Block]

Warrant Liabilities

January

2017,

we entered into a Subscription Agreement (the “Subscription Agreement”) with Acuitas Group Holdings, LLC (“Acuitas”),

one

hundred percent

(100%)

of which is owned by Terren S. Peizer, Chairman and Chief Executive Officer of the Company, pursuant to which we will receive aggregate gross proceeds of

$1,300,000

(the “Loan Amount”) in consideration of the issuance of (i) an

Series B Convertible Debenture due

March

31,

2017

(the

“January

2017

Convertible Debenture”) and (ii)

five

-year warrants to purchase shares of the Company’s common stock in an amount equal to

one

hundred percent

(100%)

of the initial number of shares of common stock issuable upon the conversion of the

January

2017

Convertible Debenture, at an exercise price of

$5.10

per share (the

“January

2017

Warrants”). The Loan Amount is payable in tranches through

March

31,

2017,

and as of

March

31,

2017

we have received

$1,115,000.

In addition, any warrants issued in conjunction with the

December

2016

Convertible Debenture currently outstanding with Acuitas have been increased by an additional

25%

warrant coverage, exercisable for an aggregate of

137,883

shares of the Company’s common stock. Acuitas agreed to extend the maturity date of the

January

2017

Convertible Debenture to

April

30,

2017

or until we complete a public offering, whichever comes

first.

The

January

2017

Warrants include, among other things, price protection provisions pursuant to which, subject to certain exempt issuances, the then exercise price of the

January

2017

Warrants will be adjusted if the Company issues shares of common stock at a price that is less than the then exercise price of the

January

2017

Warrants. Such price protection provisions will remain in effect until the earliest of (i) the termination date of the

January

2017

Warrants, (ii) such time as the

January

2017

Warrants are exercised or (iii) contemporaneously with the listing of the Company’s shares of common stock on a registered national securities exchange.

In connection with the Subscription Agreement described above, the number of Shamus warrants issued as part of the

December

2016

Convertible Debenture were increased from

75%

100%

warrant coverage, exercisable for an aggregate of

58,824

shares of the Company’s common stock.

The warrant liabilities were calculated using the Black-Scholes model based upon the following assumptions:

	March 31, 201 7
Expected volatility		93.56%
Risk-free interest rate	1.27	-	1.93%
Weighted average expected lives in years	2	-	5
Expected dividend		0%

We have issued warrants to purchase common stock in

February

2012,

April

2015,

July

2015,

August

2016,

December

2016,

January

2017,

February

2017

and

March

2017.

For the

three

months ended

March

31,

2017

and

2016,

we recognized a loss of

$5.2

million and

$228,000,

respectively, related to the revaluation of our warrant liabilities.

Derivatives, Policy [Policy Text Block]

Derivative Liability

July

2015,

we entered into a

$3.55

million

12%

Original Issue Discount Convertible Debenture due

January

18,

2016

with Acuitas (the

“July

2015

Convertible Debenture”). The conversion price of the

July

2015

Convertible Debenture is

$11.40

per share, subject to adjustments, including for issuances of common stock and common stock equivalents below the then current conversion or exercise price, as the case

may

be. In

October

2015,

we entered into an amendment of the

July

2015

Convertible Debenture which extended the maturity date of the

July

2015

Convertible Debenture from

January

18,

2016

January

18,

2017.

In addition, the conversion price of the

July

2015

Convertible Debenture was subsequently adjusted to

$1.80

per share. The

July

2015

Convertible Debenture is unsecured, bears interest at a rate of

12%

July

2015

Convertible Debenture to

April

30,

2017

or until we complete a public offering, whichever comes

first.

The derivative liability associated with the

July

2015

Convertible Debenture was calculated using the Black-Scholes model based upon the following assumptions:

	March 31, 201 7
Expected volatility		93.56	%
Risk-free interest rate		0.74	%
Weighted average expected lives in years		0.08
Expected dividend		0	%

For the

three

months ended

March

31,

2017

and

2016,

we recognized a loss of

$10.6

million and

$1.3

million related to the revaluation of our derivative liability, respectively.

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Issued or Newly Adopted Accounting Standards

April

2016,

the FASB issued Accounting Standards Update (“ASU”)

2016

10,

Revenue from Contracts with Customers (Topic

606)

, which amends certain aspects of the Board’s new revenue standard, ASU

2014

09,

Revenue from Contracts with Customers. The standard should be adopted concurrently with adoption of ASU

2014

09,

which is effective for annual and interim periods beginning after

December

15,

2017.

Early adoption is permitted. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

March

2016,

the FASB issued ASU

2016

09,

Compensation — Stock Compensation (Topic

718):

Improvements to Employee Share-Based Payment Accounting

(“ASU

2016

09”),

December

15,

2016,

and interim periods within those annual periods. Early adoption is permitted. The adoption of ASU

2016

did not have a material effect on our consolidated financial positon or results of operations.

February

2015,

the FASB issued ASU,

Consolidation (Topic

810):

Amendments to the Consolidation Analysis

(“ASU

2015

02”).

ASU

2015

modifies existing consolidation guidance for reporting organizations that are required to evaluate whether they should consolidate certain legal entities. ASU

2015

is effective for fiscal years and interim periods within those years beginning after

December

15,

2015,

and requires either a retrospective or a modified retrospective approach to adoptions. The adoption of ASU

2015

did not have a material effect on our consolidated financial position or results of operations.

August

2014,

the FASB issued FASB ASU

2014

15,

Presentation of Financial Statements—Going Concern (Subtopic

205

40):

Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern

(“ASU

2014

15”)

ASU

2014

may

one

2014

is effective for periods beginning after

December

15,

2016.

The adoption of ASU

2014

did not have a material effect on our consolidated position or results of operations.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2017

Notes Tables

Share-based Compensation, Stock Options, Activity [Table Text Block]

			Weighted Avg.
	Shares		Exercise Price
Balance December 31, 2016		244,000	$	39.06

Granted		-	$	-
Cancelled		-	$	-

Balance March 31, 2017		244,000	$	38.90

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

	Balance at March 31, 2017


(Amounts in thousands)	Level I		Level II		Level III		Total
Certificates of deposit		106		-		-		106
Total assets		106		-		-		106

Warrant liabilities		-		-		12,893		12,893
Derivative Liability						18,718		18,718
Total liabilities		-		-		31,611		31,611

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

	Level III			Level III
	Warrant			Derivative
(Dollars in thousands)	Liabilities		(Dollars in thousands)	Liabilities
Balance as of December 31, 2016	$	5,307	Balance as of December 31, 2016	$	8,122
Issuance of warrants		2,405	Issuance of warrants		-
Change in fair value		5,181	Change in fair value		10,596
Balance as of March 31, 2017	$	12,893	Balance as of March 31, 2017	$	18,718

Issuance (exercise) of warrants, net		-	Issuance (exercise) of warrants, net		-
Change in fair value		-	Change in fair value		-
Balance as of June 30, 2016	$	12,893	Balance as of June 30, 2016	$	18,718

Issuance (exercise) of warrants, net		-	Issuance (exercise) of warrants, net		-
Expiration of warrants		-	Expiration of warrants		-
Change in fair value		-	Change in fair value		-
Balance as of September 30, 2016	$	12,893	Balance as of September 30, 2016	$	18,718

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]

	March 31, 201 7
Expected volatility		93.56%
Risk-free interest rate	1.27	-	1.93%
Weighted average expected lives in years	2	-	5
Expected dividend		0%

	March 31, 201 7
Expected volatility		93.56	%
Risk-free interest rate		0.74	%
Weighted average expected lives in years		0.08
Expected dividend		0	%

XML 25 R14.htm IDEA: XBRL DOCUMENT

Note 1 - Basis of Consolidation, Presentation and Going Concern (Details Textual) - USD ($)	1 Months Ended	3 Months Ended
	Apr. 30, 2017	Mar. 31, 2017	Mar. 31, 2016
Cash Equivalents, at Carrying Value		$ 291,000
Working Capital Deficit		32,400,000
Net Cash Provided by (Used in) Operating Activities, Continuing Operations		$ (1,615,000)	$ (1,518,000)
Subsequent Event [Member]
Proceeds from Issuance of Common Stock	$ 16,500,000

XML 26 R15.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Details Textual)	1 Months Ended	3 Months Ended
	Jan. 31, 2017 USD ($) $ / shares shares	Mar. 31, 2017 USD ($) shares	Mar. 31, 2016 USD ($) shares	Dec. 31, 2016	Oct. 31, 2015 $ / shares	Jul. 31, 2015 USD ($) $ / shares
Cash, Uninsured Amount		$ 115,038
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount \| shares		1,928,431	620,119
Share-based Compensation		$ 127,000	$ 174,000
Derivative, Gain (Loss) on Derivative, Net		(5,200,000)	(228,000)
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings		$ 10,600,000	$ 1,300,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross \| shares		0	0
Income Tax Expense (Benefit)		$ 0	$ 2,000
Acuitas [Member] \| July 2015 Convertible Debenture [Member]
Debt Instrument, Interest Rate, Stated Percentage						12.00%
Debt Instrument, Face Amount						$ 3,550,000
Debt Instrument, Convertible, Conversion Price \| $ / shares					$ 1.80	$ 11.40
Acuitas [Member] \| January 2017 Warrants [Member]
Warrant Term	5 years
Class of Warrant or Right, Percent of Securities Called by Warrants or Rights Upon Conversion	100.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 5.10
Acuitas [Member] \| December 2016 Warrants [Member]
Class of Warrant or Right, Percent of Securities Called by Warrants or Rights Upon Conversion				25.00%
Class of Warrant or Right, Additional Percent of Securities Called by Warrants or Rights Upon Conversion	25.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares	137,883
Acuitas [Member] \| January 2017 Convertible Debenture [Member]
Proceeds from Issuance of Debt	$ 1,300,000	$ 1,115,000
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Conversion Of December 2016 Convertible Debentures Into Common Stock [Member] \| Shamus [Member]
Debt Conversion, Converted Instrument, Shares Issued \| shares		214,514
Common Stock Issued for Investor Relation Services [Member]
Stock Issued During Period, Shares, Issued for Services \| shares		14,492	0
Shamus Warrants [Member] \| Shamus [Member]
Class of Warrant or Right, Percent of Securities Called by Warrants or Rights Upon Conversion				75.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares	58,824
Employees and Directors [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		$ 191,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		1 year 189 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross \| shares		0	0
Minimum [Member] \| Furniture and Equipment [Member]
Property, Plant and Equipment, Useful Life		2 years
Minimum [Member] \| Leasehold Improvements [Member]
Property, Plant and Equipment, Useful Life		5 years
Maximum [Member] \| Furniture and Equipment [Member]
Property, Plant and Equipment, Useful Life		7 years
Maximum [Member] \| Leasehold Improvements [Member]
Property, Plant and Equipment, Useful Life		7 years
Twenty Seventeen Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized \| shares		2,333,334
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number \| shares		243,853
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant \| shares		50,774
Share-based Compensation		$ 127,000	$ 174,000
Twenty Seventeen Stock Incentive Plan [Member] \| Employees and Directors [Member]
Share-based Compensation		127,000	174,000
Twenty Seventeen Stock Incentive Plan [Member] \| Nonemployees [Member]
Share-based Compensation		$ 0	$ 0
Twenty Seventeen Stock Incentive Plan [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		3 years
Twenty Seventeen Stock Incentive Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		5 years
Sales Revenue, Net [Member] \| Customer Concentration Risk [Member] \| Three Customers [Member]
Concentration Risk, Number of Customers		3
Concentration Risk, Percentage		94.00%
Accounts Receivable [Member] \| Customer Concentration Risk [Member] \| Two Customers [Member]
Concentration Risk, Number of Customers		2
Concentration Risk, Percentage		79.00%

XML 27 R16.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies - Employee and Director Stock Option Activity (Details) - $ / shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Granted (in shares)	0	0
Employees and Directors [Member]
Balance (in shares)	244,000
Balance (in dollars per share)	$ 39.06
Granted (in shares)	0	0
Granted (in dollars per share)
Cancelled (in shares)
Cancelled (in dollars per share)
Balance (in shares)	244,000
Balance (in dollars per share)	$ 38.90

XML 28 R17.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies - Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Certificates of deposit	$ 106
Total assets	106
Warrant liabilities	12,893	$ 5,307
Derivative Liability	18,718
Total liabilities	31,611
Fair Value, Inputs, Level 1 [Member]
Certificates of deposit	106
Total assets	106
Warrant liabilities
Derivative Liability
Total liabilities
Fair Value, Inputs, Level 2 [Member]
Certificates of deposit
Total assets
Warrant liabilities
Derivative Liability
Total liabilities
Fair Value, Inputs, Level 3 [Member]
Certificates of deposit
Total assets
Warrant liabilities	12,893
Derivative Liability	18,718
Total liabilities	$ 31,611

XML 29 R18.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies - Fair Value Measurements Using Significant Level III Inputs (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Sep. 30, 2016
Warrants [Member]
Balance	$ 5,307	$ 12,893
Issuance (exercise) of warrants, net	2,405
Change in fair value	5,181
Balance	12,893	12,893
Derivative Financial Instruments, Liabilities [Member]
Balance	8,122	18,718
Issuance (exercise) of warrants, net
Change in fair value	10,596
Balance	$ 18,718	$ 18,718

XML 30 R19.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies - Fair Value Assumptions (Details)	3 Months Ended
	Mar. 31, 2017
Derivative Liability [Member]
Expected volatility	93.56%
Risk-free interest rate	0.74%
Weighted average expected lives in years (Year)	29 days
Expected dividend	0.00%
Warrant Liability [Member]
Expected volatility	93.56%
Expected dividend	0.00%
Warrant Liability [Member] \| Minimum [Member]
Risk-free interest rate	1.27%
Weighted average expected lives in years (Year)	2 years
Warrant Liability [Member] \| Maximum [Member]
Risk-free interest rate	1.93%
Weighted average expected lives in years (Year)	5 years

XML 31 R20.htm IDEA: XBRL DOCUMENT

Note 3 - Related Party Disclosure (Details Textual) - USD ($)	1 Months Ended	3 Months Ended
	Jan. 31, 2017	Mar. 31, 2017	Dec. 31, 2016
Due to Related Parties, Current		$ 10,046,000	$ 9,796,000
Chairman and Chief Executive Officer [Member]
Due to Related Parties, Current		204,000
Chairman and Chief Executive Officer [Member] \| Deferred Salaries [Member]
Due to Related Parties, Current		1,100,000
Shamus [Member] \| Conversion Of December 2016 Convertible Debentures Into Common Stock [Member]
Debt Conversion, Original Debt, Amount		$ 1,300,000
Debt Conversion, Converted Instrument, Shares Issued		214,514
Shamus Warrants [Member] \| Shamus [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	14,706
Class of Warrant or Right, Percent of Securities Called by Warrants or Rights Upon Conversion	100.00%		75.00%
Acuitas [Member] \| December 2016 Warrants [Member]
Class of Warrant or Right, Additional Percent of Securities Called by Warrants or Rights Upon Conversion	25.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	137,883
Acuitas [Member] \| January 2017 Convertible Debenture [Member]
Proceeds from Issuance of Debt	$ 1,300,000	$ 1,115,000

XML 32 R21.htm IDEA: XBRL DOCUMENT

Note 4 - Short-term Debt (Details Textual) - Acuitas [Member] - USD ($)	1 Months Ended	3 Months Ended
	Jan. 31, 2017	Mar. 31, 2017	Dec. 31, 2016
January 2017 Warrants [Member]
Warrant Term	5 years
Class of Warrant or Right, Percent of Securities Called by Warrants or Rights Upon Conversion	100.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 5.10
December 2016 Warrants [Member]
Class of Warrant or Right, Percent of Securities Called by Warrants or Rights Upon Conversion			25.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	137,883
January 2017 Convertible Debenture [Member]
Proceeds from Issuance of Debt	$ 1,300,000	$ 1,115,000
Debt Instrument, Interest Rate, Stated Percentage	8.00%

XML 33 R22.htm IDEA: XBRL DOCUMENT

Note 5 - Restatement of Financial Statements (Details Textual)	Apr. 25, 2017
Subsequent Event [Member] \| Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	6

XML 34 R23.htm IDEA: XBRL DOCUMENT

Note 6 - Subsequent Event (Details Textual)	Apr. 25, 2017 USD ($) $ / shares shares	Mar. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2016 USD ($)
Warrant Liabilities, Noncurrent \| $		$ 12,893,000	$ 5,307,000
Subsequent Event [Member] \| Public Offering [Member] \| Joseph Gunner & Co. LLC [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	156,250
Stock Issued During Period, Shares, New Issues	3,125,000
Shares Issued, Price Per Share \| $ / shares	$ 4.80
Shares Issued, Price Per Share, Net \| $ / shares	$ 4.464
Net Proceeds from Issuance or Sale of Equity \| $	$ 14,800,000
Class of Warrant or Right, Value of Securities Called \| $	$ 100
Class of Warrant or Right, Exercise Price of Warrants or Rights, Percent of Share Price	125.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 6
Subsequent Event [Member] \| Over-Allotment Option [Member] \| Joseph Gunner & Co. LLC [Member]
Stock Issued During Period, Shares, New Issues	303,750
Additional Shares Available for Purchase	468,750
Subsequent Event [Member] \| Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	6
Convertible Debentures [Member]
Debt Instrument, Extended Maturity \| $		$ 10,000,000
Amended Warrants [Member]
Class of Warrant or Right, Number of Additional Securities Called by Each Warrant or Right \| $ / shares		$ 0.20
Warrants not Subject to Amendment [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		11,049

EXCEL 35 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 36 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 37 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 39 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 78 164 1 false 41 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.catasyshealth.com/20170331/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.catasyshealth.com/20170331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.catasyshealth.com/20170331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.catasyshealth.com/20170331/role/statement-condensed-consolidated-statements-of-operations-unaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited) Sheet http://www.catasyshealth.com/20170331/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited- Condensed Consolidated Statement of Cash Flows (Unaudited) Statements 5 false false R6.htm 005 - Disclosure - Note 1 - Basis of Consolidation, Presentation and Going Concern Sheet http://www.catasyshealth.com/20170331/role/statement-note-1-basis-of-consolidation-presentation-and-going-concern Note 1 - Basis of Consolidation, Presentation and Going Concern Notes 6 false false R7.htm 006 - Disclosure - Note 2 - Summary of Significant Accounting Policies Sheet http://www.catasyshealth.com/20170331/role/statement-note-2-summary-of-significant-accounting-policies Note 2 - Summary of Significant Accounting Policies Notes 7 false false R8.htm 007 - Disclosure - Note 3 - Related Party Disclosure Sheet http://www.catasyshealth.com/20170331/role/statement-note-3-related-party-disclosure Note 3 - Related Party Disclosure Notes 8 false false R9.htm 008 - Disclosure - Note 4 - Short-term Debt Sheet http://www.catasyshealth.com/20170331/role/statement-note-4-shortterm-debt Note 4 - Short-term Debt Notes 9 false false R10.htm 009 - Disclosure - Note 5 - Restatement of Financial Statements Sheet http://www.catasyshealth.com/20170331/role/statement-note-5-restatement-of-financial-statements Note 5 - Restatement of Financial Statements Notes 10 false false R11.htm 010 - Disclosure - Note 6 - Subsequent Event Sheet http://www.catasyshealth.com/20170331/role/statement-note-6-subsequent-event Note 6 - Subsequent Event Notes 11 false false R12.htm 011 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.catasyshealth.com/20170331/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.catasyshealth.com/20170331/role/statement-note-2-summary-of-significant-accounting-policies 12 false false R13.htm 012 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) Sheet http://www.catasyshealth.com/20170331/role/statement-note-2-summary-of-significant-accounting-policies-tables Note 2 - Summary of Significant Accounting Policies (Tables) Tables http://www.catasyshealth.com/20170331/role/statement-note-2-summary-of-significant-accounting-policies 13 false false R14.htm 013 - Disclosure - Note 1 - Basis of Consolidation, Presentation and Going Concern (Details Textual) Sheet http://www.catasyshealth.com/20170331/role/statement-note-1-basis-of-consolidation-presentation-and-going-concern-details-textual Note 1 - Basis of Consolidation, Presentation and Going Concern (Details Textual) Details http://www.catasyshealth.com/20170331/role/statement-note-1-basis-of-consolidation-presentation-and-going-concern 14 false false R15.htm 014 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.catasyshealth.com/20170331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual Note 2 - Summary of Significant Accounting Policies (Details Textual) Details http://www.catasyshealth.com/20170331/role/statement-note-2-summary-of-significant-accounting-policies-tables 15 false false R16.htm 015 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Employee and Director Stock Option Activity (Details) Sheet http://www.catasyshealth.com/20170331/role/statement-note-2-summary-of-significant-accounting-policies-employee-and-director-stock-option-activity-details Note 2 - Summary of Significant Accounting Policies - Employee and Director Stock Option Activity (Details) Details 16 false false R17.htm 016 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Sheet http://www.catasyshealth.com/20170331/role/statement-note-2-summary-of-significant-accounting-policies-fair-value-assets-and-liabilities-measured-on-recurring-basis-details Note 2 - Summary of Significant Accounting Policies - Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Details 17 false false R18.htm 017 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Fair Value Measurements Using Significant Level III Inputs (Details) Sheet http://www.catasyshealth.com/20170331/role/statement-note-2-summary-of-significant-accounting-policies-fair-value-measurements-using-significant-level-iii-inputs-details Note 2 - Summary of Significant Accounting Policies - Fair Value Measurements Using Significant Level III Inputs (Details) Details 18 false false R19.htm 018 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Fair Value Assumptions (Details) Sheet http://www.catasyshealth.com/20170331/role/statement-note-2-summary-of-significant-accounting-policies-fair-value-assumptions-details Note 2 - Summary of Significant Accounting Policies - Fair Value Assumptions (Details) Details 19 false false R20.htm 019 - Disclosure - Note 3 - Related Party Disclosure (Details Textual) Sheet http://www.catasyshealth.com/20170331/role/statement-note-3-related-party-disclosure-details-textual Note 3 - Related Party Disclosure (Details Textual) Details http://www.catasyshealth.com/20170331/role/statement-note-3-related-party-disclosure 20 false false R21.htm 020 - Disclosure - Note 4 - Short-term Debt (Details Textual) Sheet http://www.catasyshealth.com/20170331/role/statement-note-4-shortterm-debt-details-textual Note 4 - Short-term Debt (Details Textual) Details http://www.catasyshealth.com/20170331/role/statement-note-4-shortterm-debt 21 false false R22.htm 021 - Disclosure - Note 5 - Restatement of Financial Statements (Details Textual) Sheet http://www.catasyshealth.com/20170331/role/statement-note-5-restatement-of-financial-statements-details-textual Note 5 - Restatement of Financial Statements (Details Textual) Details http://www.catasyshealth.com/20170331/role/statement-note-5-restatement-of-financial-statements 22 false false R23.htm 022 - Disclosure - Note 6 - Subsequent Event (Details Textual) Sheet http://www.catasyshealth.com/20170331/role/statement-note-6-subsequent-event-details-textual Note 6 - Subsequent Event (Details Textual) Details http://www.catasyshealth.com/20170331/role/statement-note-6-subsequent-event 23 false false All Reports Book All Reports cats-20170331.xml cats-20170331.xsd cats-20170331_cal.xml cats-20170331_def.xml cats-20170331_lab.xml cats-20170331_pre.xml true true ZIP 41 0001437749-17-009273-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-17-009273-xbrl.zip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end